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Abstract 
 
In recent decades, research has unravelled fascinating detail about the molecular 
mechanisms underpinning pharmacologic loss of consciousness (LOC). However, 
the systems-level mechanisms are far less clear. Recent genetic approaches, 
however, enable unprecedented dissection on neural pathways, and they are paving 
a way for this line of research. The focus of this thesis is to investigate the 
neuroanatomical substrates of commonly used drugs which reversibly render us 
unconscious. 
 
Zolpidem is a positive allosteric modulator (PAM) of the GABAA receptor which binds 
to the benzodiazepine (BZ) site. Because zolpidem binds 1-3,,2 containing 
GABAA receptors, which are widespread, it acts virtually everywhere. We do not 
know if zolpidem causes sleep by enhancing GABAergic inhibition throughout the 
entire brain, or if the therapeutic sleep-inducing property depends upon specific brain 
circuitry. 2I77 mice are devoid of zolpidem-sensitivity. But, zolpidem-sensitivity can 
be restored selectively in brain regions, enabling dissection of the circuitry involved 
in zolpidem’s effect. To isolate the therapeutic effect of zolpidem we deleted GABAA-
2I77-subunits and replaced them with GABAA-2F77-subunits in HDC neurons or 
frontal-cortex in isolation. We were able to selectively restore zolpidem-sensitivity in 
target neurons. This conferred zolpidem-enhanced IPSCs locally. Compared with 
wild-type mice and zolpidem-insensitive 2I77lox mice, we found that GABAA-2F77 
receptors in either HDC-neurons or frontal cortex alone were enough to rescue the 
majority of zolpidem-mediated sleep. The response in HDC-2F77 mice was similar 
to that of an H1-receptor antagonist. By producing a null effect in a negative-control 
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area – the superior colliculus – we show that HDC neurons and the frontal cortex are 
both substrates involved in zolpidem-mediated sleep. 
 
We also investigated the role of synaptic-inhibition onto corticothalamic-neurons in 
anaesthetic-induced LOC and sleep-wake. To do this, we genetically ablated 2-
subunits from layer-6 corticothalamic-cells by crossing Ntsr1-Cre mice with GABAA-
2I77lox mice. We found this reduced isoflurane sensitivity, but left sleep-wake 
behaviours virtually unaffected. 
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1. Introduction  
 
Drugs that safely induce loss of consciousness (LOC) are extremely important in our 
society. Correcting insomnia is crucial for public health, and anaesthesia is a 
keystone in surgery. But these drugs also offer an opportunity to learn about how 
consciousness is controlled. Sleep is a vital behaviour, but it is one of the remaining 
mysteries in life sciences. We still do not fully understand how it is regulated. Even 
defining consciousness can be challenging, hence the tagline “The hard problem”. 
Drugs that induce LOC are becoming well characterized at the molecular level, i.e. 
target receptors. Lagging behind is the systems-level understanding of how these 
drugs work, and understanding this is the primary focus of this thesis. A drug’s action 
upon a receptor can conceptually be fairly simplistic; for instance, it may open a 
channel – the details may be complicated, but ultimately a receptor either facilitates 
depolarization or hyperpolarization of the cell. However, depending on the type of 
neuron the targeted receptor belongs to, different net effects can occur. And many 
different types of neurons and brain nuclei, which confer different behaviours, can 
utilize the same types of receptors. So, overall behavioural outputs of drugs can be 
complex. In the following paragraphs I will discuss the techniques that we use to 
understand vigilance states such as sleep, wake and anaesthesia. I will also give a 
description of the key drugs focused on in this piece of work. And I will write about 
specific parts of the brain which are involved in the control of sleep-wake, plus 
functionality which may produce consciousness, and how drugs can influence these 
mechanisms to remove consciousness in a reversible way. 
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There are a number of approaches available in neuroscience to ascribe specific 
molecules, cell populations, anatomy and circuitry to behaviours. Applying them to 
sleep research is teaching us new things about the way our sleep and waking is 
controlled. Classic genetic approaches involve deleting a gene which encodes a 
protein, using Cre-recombinase (Cre) which deactivates sequences flanked by LoxP 
sites (floxed) (Nagy, 2000, Rossant and Mcmahon, 1999). This may be a receptor or 
enzyme for example. By restricting the deletion to a population of cells, we can infer 
that the behavioural out-come reveals the role of the protein in behaviour. However 
this subtractive approach can lead to difficulties interpreting negative results. Either 
the deleted protein is expendable, or it is so important that the function has been 
replaced by genetic compensation (Havekes and Abel, 2009, Wisden et al., 2009). 
Lesion studies using toxins provide information about neuroanatomy in a similar way 
(Fuller et al., 2011). However this approach is also susceptible to dampened effects 
because of neuronal plasticity, and the approach offers no insight into molecular 
level mechanisms. Drugs can provide a powerful means of investigating behaviour, 
because drugs have short-acting reversible effects compensation in less of a 
concern. But drugs offer no spatial resolution, except for radiolabelled ligands. 
However, radiolabelled ligands do not provide information about a particular brain 
region’s role in the drug’s behavioural output. The same limitation comes with 
imaging studies. 
 
Patch-clamp techniques reveal a great deal of information about how drugs interact 
with specific brain areas, and the functional connectivity between different parts of 
brain circuitry. However collecting this information with respect to behaviour can be 
difficult, and consequently using this approach for behaviour has not become a 
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widespread standard lab practice. Pharmacogenetics (also called chemogenetics) 
and virus-mediated transgenic techniques have become powerful tools, because 
they merge the advantages of some of these approaches and circumvent some of 
the pitfalls of genetic compensation, because they can be implemented in adulthood 
(Nichols and Roth, 2009, Betley and Sternson, 2011, Wulff and Wisden, 2005, 
Shevtsova et al., 2005). By introducing receptors into restricted and defined areas of 
the brain, then activating the receptors with an otherwise inert drug, we have an 
approach which is short-acting and reversible as well as anatomically specific. And 
this can produce behavioural outputs. Although pharmacogenetic approaches are 
good for exciting and inhibiting populations of cells, the effects of these exogenously 
introduced receptors do not necessarily reflect the dynamic profile of an actual 
therapeutic drug or endogenous ligand. So these various approaches should be 
used together to probe the functions of the brain. We aim to use a combination of 
some of these techniques to probe the pathways involved in sleep-wake control, and 
how sedative-hypnotic drugs and anaesthetics may influence these pathways to 
produce their therapeutic effects. 
 
1.1 Electroencephalography (EEG) signals and sleep-wake 
 
Often, when investigating LOC, behaviour is the primary parameter. For example, 
patients in comas or vegetative states may be assessed based on whether they can 
interact with the clinician (Alkire et al., 2008, Franks, 2008). However more 
sophisticated tools can be employed which offer biophysical markers of the vigilance 
states of people and animals. EEG has become a principal technique for this, as the 
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signals provide correlates of behaviours including rapid-eye-movement (REM) sleep, 
non-rapid-eye-movement (NREM) sleep and wakefulness. 
 
EEG and certain defined signal profiles are often described with little or no indication 
of what the signals physically represent. As EEG is a key measure in many of the 
experiments in this body of work, a brief description would be useful here. EEG 
signals can arise anywhere in the brain, but because recording electrodes are placed 
above the neocortex, they emerge primarily from the neocortex with some signals 
coming from the hippocampus and the medial septum (Buzsáki et al., 2012). The 
neurons of the neocortex are made up of about 80% pyramidal cells, which are 
glutamatergic excitatory neurons. The rest are various classes of GABAergic 
inhibitory interneurons (Harris and Mrsic-Flogel, 2013). Cortical pyramidal neurons 
have apical dendrites which can span the thickness of the cortex (Briggs, 2010). 
They are organized in an “upright” position - meaning the apical dendrites point up 
and outward, perpendicular to the surface of the cortex (Da Silva, 2013). When 
excitatory post-synaptic potentials (EPSPs) and inhibitory post-synaptic potentials 
(IPSPs) fluctuate within groups of neurons, ionic currents are produced which flow 
between intracellular and extracellular space. Action potentials are not necessary for 
an EEG signal, although they do contribute. This activity produces transient electrical 
sinks and sources in the extracellular medium (Buzsáki et al., 2012). And these 
electrical signals from individual cells sum on the vertical axes to produces a signal 
known as the local field potential (LFP; Figure 1.1). In other words, an LFP is the 
extracellular electrical potential of a cluster of neighbouring neurons. LFPs constitute 
the building blocks of the EEG signal, which is a more broad measure and takes the 
form of a complex sinusoidal signal (Da Silva, 2013, Ellender and Paulsen, 2010). 
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Figure 1.1. Schematic diagram of how LFPs are generated. 
Synaptic activity on pyramidal neurons produces ionic currents across the 
membrane (red arrow loops). This leads to sinks and sources which, together, 
produce an electrical potential of a group of proximal neurons (blue ellipse). The 
potential fluctuates relative to other groups of neurons and provides a degree of 
synchrony. LFPs are the units of the EEG signal. Drawn by D.S. Uygun with 
reference to Da Silva (2013) 
 
One of the key defining features of the EEG signal is synchrony. A “synchronized” 
EEG signal is characterized by slow, high amplitude waves (Figure 1.2. a)(Muzur et 
al., 2002). It means that many neurons are depolarizing and repolarizing together in 
concert. This enables a larger signal which rises and falls together. A 
“desynchronized” signal, on the other hand, is a low amplitude signal with faster 
frequencies forming a steadier – or “flatter” – appearance than a synchronized signal 
(Figure 1.2. b)(Muzur et al., 2002). Desynchronized EEG indicates that many groups 
of neurons are oscillating at different frequencies - indicating more functional or 
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communicative independence from one another. So, this pattern of activity cannot 
summate to produce larger waves (Figure 1.2.). 
Figure 1.2 EEG of 
wakefulness vs EEG 
of NREM. 
a example trace of 
synchronized EEG 
taken during one 
minute of NREM 
sleep in a mouse. A 
one second period is 
blown-up. b example 
trace of 
desynchronized EEG 
from the same animal 
during waking. A one 
second period is 
blown-up. c Fast 
Fourier Transform 
(FFT) performed on 
the EEG traces which 
shows power of the 
various frequencies. 
During NREM sleep 
slower frequencies 
dominate. During 
waking these slower 
frequencies represent 
less of the profile 
than faster 
frequencies. Drawn 
by D.S. Uygun with 
unpublished data 
recorded from a 
C57BL/6 mouse. 
 
 
 
Oscillations within specific frequency bands have been named, and ascribing 
oscillatory characteristics to behaviours and brain states is an ongoing active branch 
of neuroscience. -rhythms are frequencies between ~ 8 Hz and ~ 13 Hz and they 
are associated with relaxed, eyes-shut (Palva and Palva, 2007), waking. -rhythms 
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are frequencies between ~13 Hz and ~ 30 Hz and associated with active cognitive 
function. -rhythms are fast oscillations, typically above 30Hz and up to ~ 100Hz 
(Fries, 2009) and often cited as a 40Hz rhythm (Baker, 2007). It is less clear what -
rhythms signify, but some studies have claimed that they represent or aid cognitive 
processes. For example, studies have posited that -oscillations are important for 
binding together information into mental percepts, therefore playing a role in working 
memory, memory consolidation and encoding information (Fries, 2009). Because -
oscillations are fast, the underlying neuronal activity takes place on a ~6 to ~12 
millisecond (ms) time scale. It is thought, this precision of timing is important for 
synchronizing functionally connected brain areas. And this may be a mechanism of 
information integration from lower to higher order brain areas (Fries, 2009). 
Interestingly, quantitative EEG shows that -oscillation coherence – the coupling of 
oscillatory activity between distal cortical regions (left mesial prefrontal vs occipital) –
returns sooner than coherence of other frequency bands while emerging from 
anaesthesia. Patients become responsive, and are therefore conscious, for a period 
of time when only -oscillations are coherent (John and Prichep, 2005). -rhythms 
are slow, oscillations between ~1 Hz and ~4 Hz; and sub 1Hz activity is termed slow 
wave activity (SWA). -oscillations and SWA are important for studying sleep, as 
they constitute a key marker of NREM sleep (Murphy et al., 2009). -rhythms are 
oscillations between ~4 Hz and ~8Hz and have been ascribed to many different 
things but are a main feature in actively behaving animals (Hasselmo, 2005). 
 
As EEG is recorded with time plotted on the x-axis, various frequencies are present 
and the signal manifests with many sinusoidal waves on top of one another. It 
becomes difficult to assess the relative proportions of frequency bands within the 
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signal. Various signal processing strategies are needed to provide this information. 
Fast-Fourier transform (FFT) is used to determine the composition of different 
frequencies within a signal over a fixed period of time. Here, the frequencies are 
plotted on the x-axis, the time parameter is lost, and power of specific frequency bins 
can be determined. Frequency power spectra can provide a clearer indication of 
different vigilance states. 
 
For example, the characteristic profile of NREM sleep is predominant -power 
(Murphy et al., 2009) (Figure 1.2. c). During wakefulness,-rhythms dominate, 
although -rhythms are also present. But after a transition into NREM sleep, -power 
increases to become the most abundant rhythm. Thus, the  ratio is a useful 
measure for determining NREM sleep and other vigilance states. REM sleep, also 
known as paradoxical sleep, produces an EEG frequency power spectrum similar to 
waking. Therefore an additional electrophysiological measure is needed to 
differentiate, and electromyography (EMG) is commonly used. During REM sleep, 
paralysis sets in (the exception being REM-sleep behavioural disorder), which is an 
adaptive feature controlled by the mediodorsal pontine tegmental areas of the 
brainstem (Schenck and Mahowald, 2002). REM sleep occurs after bouts of NREM 
sleep, therefore “wake-like” EEG following periods of NREM sleep, paired with 
muscle atonia indicates REM sleep. Interestingly, -rhythms also peak in REM sleep 
when the person or animal it is not moving around. In humans, dreaming is thought 
to be associated with REM sleep (Maquet et al., 1996, Hobson, 2009). So, it may be 
that -oscillations are a general indicator of “experiencing”. In lab animals, waking, 
NREM sleep and REM sleep are the three main vigilance states. In humans, NREM 
sleep is further broken down into four stages characterized by how human subjects 
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subjectively respond to being woken up and sequential changes of EEG activity over 
the course of a sleep episode (American Sleep Association, 2007). Although distinct 
stages of sleep have been described in lab animals, such as the rat, they are not 
routinely used in sleep-wake analysis (Gottesmann, 1992). 
 
1.2 Sleep disruption and disorders: insomnia 
 
This section will not be an exhaustive description of sleep disruptions and disorders, 
but rather it should highlight two main points. Firstly, avoiding challenges to good 
healthy sleep is difficult. Secondly, it is very important that poor or insufficient sleep 
is remedied. The International Classification of Sleep Disorders (version 2) (Thorpy, 
2012, Roth, 2007, Roth et al., 2011, American Academy of Sleep Medicine, 2001) 
describes 81 sleep disorders. They range from dramatic, acutely manifesting 
conditions such as cataplexy to the more familiar insomnias. Insomnia is the most 
common sleep disorder. It consists of complaints about onset, duration, and quality 
of sleep. Prevalence estimates vary, with reports of 10-15%, 22% and 30% (Roth et 
al., 2011, Roth, 2007, Woznica et al., 2014). Insomnia is linked to depression and 
poor general health (The National Sleep Foundation, 2014), and it is also considered 
a strain on the economy (Woznica et al., 2014). Part of the reason sleep disruption is 
so common, is because it can be caused by many things which are commonplace in 
most people’s lives. Examples include jetlag, shift work, stress and simply staying in 
an unfamiliar place overnight (Sack et al., 2007, Xu et al., 2014, Roehrs, 1998). 
 
Many animals including humans have evolved to be entrained by daylight to maintain 
a circadian sleep-wake pattern (Foster, 2012), so other sources of light can influence 
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the mechanisms which regulate this daily rhythm. Artificial light is routinely kept on 
later than sun-set in modern households. In recent years, more handheld devices 
with backlit screens (blue light) have become increasingly accessible. Recent data 
indicates that these are new sources of stimuli contributing to insomnia (Figueiro et 
al., 2009). 
 
Another major challenge to healthy sleep patterns is the availability and desirability 
of psychostimulants. For example nicotine from cigarettes provides many 
pharmacologic effects including wake promotion (Boutrel and Koob, 2004, Irish et al., 
2014). Nicotine is an agonist of the nicotinic acetylcholine receptor, which is a 
pentameric excitatory ligand gated ion channel (Wu and Lukas, 2011). When 
nicotine binds, the channel opens to sodium, potassium and calcium cations which 
depolarize neurons rapidly (Changeux, 2010). Because the cholinergic basal 
forebrain is a major arousal mechanism (Cape and Jones, 2000, Fuller et al., 2011, 
Détári, 2000), potentiating cholinergic neurophysiology in the brain leads to wake 
promotion. Furthermore, paradoxically, acute withdrawal of nicotine promotes 
arousal as well (Hughes, 2007). Leading up to bedtime, this can pose a significant 
challenge to falling asleep naturally. 
 
Caffeine is another popular psychostimulant (Boutrel and Koob, 2004, Irish et al., 
2014, Roehrs and Roth, 2008). It is a competitive antagonist of A1 and A2A 
adenosine receptors, and binds each with essentially the same affinity (Fredholm et 
al., 1999). Both A1 and A2A adenosine receptors have been suggested to play a role 
in physiologic sleep-wake regulation (Strecker et al., 2000) However, global genetic 
deletion of each receptor type revealed that caffeine wake-promotion requires A2A 
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receptors specifically (Huang et al., 2005). One hypothesis of homeostatic sleep 
regulation states that extracellular adenosine builds up in the basal forebrain and 
neocortex during waking and provides a “sleep-pressure” (Porkka-Heiskanen, 2013, 
Porkka-Heiskanen et al., 2000). Thus, when caffeine blocks adenosine from binding 
to the receptor, the onset of sleep is inhibited. One could assume that caffeine 
requires action at the cholinergic basal forebrain or at the neocortex to promote 
wakefulness. However, caffeine also potentiates glutamate and dopamine release 
(Solinas et al., 2002). And evidence is emerging that dopaminergic regions, including 
the ventral tegmental area (VTA) and periaqueductal grey (PAG), contribute to wake 
promotion. (Solt et al., 2014, Saper et al., 2005, Lu et al., 2006), and expression of 
A2A receptors (Dixon et al., 1996) in the the nigrostriatal dopamine pathway - but not 
the PAG – suggested the nucleus accumbens (NAc) and/or the striatum were 
needed for caffeine wake-promotion. This became clear with evidence that caffeine 
inhibits sleep locally at the shell of the nucleus accumbens (NAc). By deleting 
adenosine A2A receptors selectively in the NAc using virus-mediated Cre-lox knock-
out, Lazarus et al. (2011) removed the wake promoting property of caffeine. They 
then showed that the NAc shell, but not the NAc core, was the brain region involved, 
by using siRNA knockdown of adenosine A2A receptors in each of the two regions in 
rats. Interestingly, deleting adenosine A2A receptors in the basal forebrain did not 
affect caffeine induced wake-promotion, and the authors reported sparse A2A 
receptor expression in the neocortex. 
 
There are various ways to counter insomnia. The awareness of practices collectively 
termed “sleep hygiene” is increasing (Stepanski and Wyatt, 2003). Practices include 
keeping electronic devices such as tablet computers out of the bedroom, avoiding 
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stimulating activities just before bed time, reducing noise, and keeping regular a bed 
time (Irish et al., 2014). Going to the bedroom only to sleep, is thought to produce an 
association between the surroundings and sleeping, which forms a setting that 
promotes sleep. Although these exercises are useful, it is not necessarily practical or 
possible for everyone to follow the routines, depending on a person’s life style or 
profession. Cognitive behavioural therapy can also alleviate insomnia (Morgan et al., 
2003). But of course it requires participation in sessions and trained therapists. 
Therefore it is paramount that we have safe and reliable drugs with well 
characterised therapeutic effect profiles and mild or no side effects. 
 
1.3 Sedative-hypnotic drugs 
 
Sleep inducing drugs have been used for centuries. Early examples include a 
medieval drug called “Great rest” which was a cocktail of opiates (Everett and Gabra, 
2014). In 1805 morphine was isolated from opium, and was used in psychiatry as a 
sedative-hypnotic. In 1904, barbiturates were introduced into psychiatry (López-
Muñoz et al., 2005). They were the first class of drug to be marketed systematically 
(Healy, 2008).  Barbiturates became the mainstay sedative-hypnotics from the 1920s 
to the 1950s and became the first injectable anaesthetics. However, barbiturate-
overdose was risky and deadly, due to respiratory suppression. Also, they reacted 
with other psychiatric drugs (López-Muñoz et al., 2005). Consequently, barbiturates 
were replaced as newer drugs became available. In 1955 the first benzodiazepine 
(BZ), chlordiazepoxide (Librium) was synthesised and it was used in psychiatry from 
1960 (Mehdi, 2012). 
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During the 1950s histamine receptor antagonists, which are primarily used to treat 
allergy, became known for their sedative properties. They had been considered 
potential therapeutic sedatives, and were used mainly for children (Healy, 2008). But 
they cause next day hangover effects (Zhang et al., 2010). Tricyclic anti-depressants 
(TCA) have also been used to help patients sleep (Ware, 1983). The 
serotonin/noradrenalin reuptake inhibitor Doxepin is an example, however its sleep 
inducing properties are thought to happen via anti-histamine action (Equihua et al., 
2013). Neither anti-histamines nor TCAs, however, became popular in the way BZs 
did. During the 1960s, other BZs such as diazepam (Valium) were used clinically. 
BZs were much safer than barbiturates and became heavily prescribed throughout 
the 1960s and 1970s. BZs were also used throughout the 1980s, but by this point 
concerns about physical dependence and rebound insomnia were emerging (Kales 
et al., 1978). 
  
Z-drugs, which are also known as non-benzodiazepines because of their distinct 
chemical structures, became a replacement for BZs during the 1980s. Zopiclone, a 
cyclopyrrolone, was introduced into clinics in 1985, followed shortly by zolpidem, an 
imidazopyridine, in 1988. This was the same year that the Committee of the Safety 
of Medicines drafted a comprehensive guideline regarding the regulation of BZs, 
which marked a decrease in popularity of BZs as hypnotic agents (López-Muñoz et 
al., 2005). The second half of the 1980s was a pivotal time for modern sleep 
medicine. Today, while BZs are still popular anxiolytics, Z-drugs like zolpidem are 
the gold standard treatment for insomnia. For well over a century, all the most useful 
sedative-hypnotics – barbiturates, BZs and now Z-drugs – are all involved in 
potentiating GABAergic transmission. 
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1.4 GABAA Receptors 
 
Z-drugs and BZs are positive allosteric modulators (PAMs) of the GABAA receptor. 
The GABAA receptor is the most important target in neuronal inhibition. -
aminobutyric acid (GABA) is the main inhibitory neurotransmitter and it acts upon 
two classes of receptor: The ionotropic GABAA receptor and the metabotropic 
GABAB receptor. The GABAC receptor is also cited in the literature and is uniquely 
insensitive to many modulators (Johnston, 1996). However, the GABAC receptor, 
assembled from  subunits, was reclassified as a type of GABAA receptor (Olsen 
and Sieghart, 2009). The GABAA receptor is a pentameric ligand-gated ion channel 
(Harrison, 2006, Smart and Paoletti, 2012) and its 3D structure has recently been 
solved (human--homomer)(Miller and Aricescu, 2014). Its five protein subunits form 
a central pore through which chloride anions can flow into the cell down an 
electrochemical gradient. This gradient is maintained actively at other loci of the cell 
membrane by the K+ -Cl- co-transporter 2 (KCC2) in the adult brain (Blaesse et al., 
2009, Owens and Kriegstein, 2002). The five constituent subunits of the GABAA 
receptor can be assembled from 19 known subunit types (6, 3, 3, 1, 1, 1, 1, 
& 3) (Möhler, 2006), each containing four transmembrane domains with 
extracellular N and C termini (Michels and Moss, 2007). The 2-2-12 formation 
(Figure 1.3.) is the most abundant in the brain (Sieghart and Sperk, 2002, Franks, 
2008, Rudolph and Knoflach, 2011, Sigel and Steinmann, 2012, Smart and Paoletti, 
2012). 
 
2-subunit containing GABAA receptors localize in the synapse (Alldred et al., 2005, 
Essrich et al., 1998) and are important in fast synaptic-GABAergic inhibition 
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(Schweizer et al., 2003). However, under some circumstances, 3-subunits can 
confer synaptic GABAA receptor localization in the absence of the 2-subunit. But 
these 3-subunit containing synaptic GABAA receptors only produce “miniature” 
inhibitory post synaptic currents (mIPSCs) with significantly longer decay times if the 
2-subunit is not involved (Kerti-Szigeti et al., 2014). Also, whether 3-subunits are 
normally involved in synaptic localization, or if Kerti-Szigeti et al. (2014) observed a 
result of genetic compensation is an open question. 
 
GABA binds to sites on the hydrophilic section towards the N-termini at the 
interfaces between -subunits and -subunits (Nishikawa et al., 2002). When GABA 
binds, it causes a conformational change which opens the channel, enabling chloride 
influx (Figure 1.3, left). This rapidly hyperpolarizes the cell making it less excitable. 
PAMs are drugs which bind to a distinct site - away from the binding position of the 
endogenous ligand – where they cause a conformational change that enhances the 
apparent affinity of the endogenous ligand (Figure 1.3. centre). In the case of Z-
drugs and BZs, this happens at the BZ-site, found on the hydrophilic sections 
towards the N-termini at the interface between  and 2 subunits (Sigel and Buhr, 
1997). The molecular action of Z-drugs and BZs is subtle. When they are bound, 
GABA remains bound for longer which keeps the channel open longer. This is 
reflected by IPSC decay time, which is prolonged relative to GABA-only activation 
(Cope et al., 2004). 
 
Allosterism is important in therapeutics. Because the effects are dependent upon the 
presence of endogenous ligands, the pharmacokinetics of allosteric drugs are often 
more physiologically relevant. Their effects rely upon the naturally regulated release 
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of neurotransmitters. By contrast full agonists, for instance, do not enhance a 
neurotransmitter’s action, but rather usurp it. Allosteric targets also offer more varied 
possibilities for drug design. Receptor isoforms can be targeted selectively, whereas 
drugs which compete directly for the orthosteric site will bind indiscriminately to all 
receptor types (Christopoulos, 2002). In the next paragraphs it will become clear why 
targeting specific receptor isoforms with this level of selectivity is desirable, as this 
provides the potential to create better, more predictable and more specific drug-
effect profiles. 
 
In the brain, relatively small numbers of GABAergic interneurons influence great 
numbers of excitatory neurons. Consequently, GABAA receptors have to be 
expressed everywhere for this arrangement to be effective (Brown et al., 2010) and a 
rich arsenal of receptor isoforms are needed to encode diverse network behaviour 
(Möhler, 2006). One might assume that the summative activity across widespread 
receptors is what makes BZs and Z-drugs such powerful sedative-hypnotics. 
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Figure 1.3. Schematic of zolpidem action upon the synaptic GABAA receptor. 
Left, a wild-type GABAA receptor with zolpidem unbound. The GABA binding site 
has normal affinity for GABA. Centre, a wild-type GABAA receptor with zolpidem 
bound. A conformational change has occurred which increases the apparent affinity 
of the GABA binding pocket for GABA. GABA will stay in the pocket longer and keep 
the channel open. Right, A 2I77 point-mutant GABAA receptor. The mutation 
changes the shape of the zolpidem binging pocket - located in the BZ-site - such that 
zolpidem can no longer bind. The GABA binding site is unaltered. So GABA can still 
bind with normal affinity, but it can no longer be modulated by zolpidem. Drawn by 
D.S. Uygun. 
 
Because the GABAA receptor exists in many isoforms, it seems each type provides 
diverse and distinct influence on how behaviours are encoded. And the tendencies of 
various drugs to favour isoforms give rise to distinct pharmacologic profiles of 
individual drugs (Reynolds et al., 2003). Many sedative-hypnotic drugs have 
classically been interchangeable as anxiolytics and anti-epileptics. Point mutations of 
specific subunit types have altered the shape of the BZ-site and disturbed drug-
receptor interaction, leaving GABAA receptors containing other subunit types 
amenable to drug action. These studies have offered much insight into how certain 
drugs have overlapping, yet distinct, effects (Rudolph and Möhler, 2004). For 
example, the mature 1 subunit has a histidine at the amino-acid residue position 
101. Mutating this to an arginine (H101R) residue alters the shape of the BZ site 
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such that zolpidem and diazepam binding is diminished (Wieland et al., 1992, Sigel 
and Buhr, 1997, Kralic et al., 2002). The motor sedative properties of diazepam and 
zolpidem are attenuated in the 1H101R point mutant mouse strain (Mckernan et al., 
2000, Crestani et al., 2000, Rudolph et al., 1999). Interestingly however, in 2 
subunit point-mutant (H101R) mice, diazepam motor-sedation in conserved, but the 
anxiolytic property of the drug is attenuated, as assessed by elevated plus maze 
open arm entries (Löw et al., 2000). Further, in mice with the corresponding mutation 
in 3, H126R, diazepam motor sedation and anxiolysis is preserved, but 
myorelaxation is reduced (Löw et al., 2000, Crestani et al., 2001). Until recently, 
these point mutant studies had resulted in one GABAA receptor isoform being 
rendered insensitive, revealing which effects were deleted. Remaining drug features 
could be ascribed to the other relevant sub-types. However, Ralvenius et al. (2015) 
generated mice that were only sensitive by one GABAA receptor type; and they did 
this for each BZ sensitive isoform (1-3 & 5). In line with previous work, diazepam 
motor-sedation was present only 1-subunit sensitive mice. Motor activity levels in 
an open field were increased after diazepam injections in the mice with sensitivity 
only in 2-subunits, suggesting anxiolysis. The focus of this study was primarily on 
analgesia, however, so sleep-wake parameters were not addressed. We can learn 
from these point mutation studies that drugs like this produce effects that are actually 
complex ensembles of constituent effects, which present together depending on the 
specific GABAA receptor isoforms that are influenced. Each subunit-type has its own 
expression pattern throughout the brain (Wisden et al., 1992). So, each type may 
communicate different behaviours due to where they are situated anatomically. 
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On the mature 2-subunit, a phenylalanine at the 77th amino-acid residue position is 
important for zolpidem-sensitivity of the GABAA receptor (Buhr et al., 1997, Wingrove 
et al., 1997, Cope et al., 2004, Ogris et al., 2004). Point mutation to isoleucine 
(2I77) abolishes zolpidem’s ability to bind (Ogris et al., 2004). Consequently, 2I77 
mice are devoid of zolpidem-sensitivity. Zolpidem does not prolong their IPSCs or 
sedate them (Cope et al., 2004, Cope et al., 2005). Diazepam, on the other hand 
does enhance GABA mediated inhibitory currents via GABAA-2I77 receptors 
(maximally about two to three fold), albeit to a far lesser extent than in the wild-type 
GABAA-2F77 receptors (maximally about seven to eight fold) (Ramerstorfer et al., 
2010). Together with the -subunit work, we can infer that Z-drugs and BZs interact 
with the binding pocket of the BZ site in different ways, as well as conferring different 
behavioural effects via distinct subunit types. However, the types of GABAA receptor 
isoforms that are amenable to zolpidem binding are expressed virtually everywhere 
in the brain. So, point mutation studies are not able to tell us which drug effects are 
conferred via different brain areas. It presents the following dilemma: For a hypnotic 
like zolpidem to induce sleep does it need to enhance GABAergic transmission 
globally throughout the brain? Or, does zolpidem confer different behaviours via 
different anatomical brain regions and its sleep inducing property relies on specific 
brain circuitry, such as wake-active regions? These are important questions to 
answer because although zolpidem is a mainstay it can cause amnesic delirious 
side-effects. Patient reports include unpleasant hallucinogenic subjective 
experiences, as well as unconscious behavioural episodes (Inagaki et al., 2010). 
These are serious and potentially harmful side effects. Therefore understanding the 
necessary and dispensable anatomical substrates of zolpidem is important for 
searching for new drug targets. 
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Figure 1.4. The “2-swap” method introduces zolpidem-sensitivity selectively 
in brain areas to isolate behavioural drug effects. 
a Zolpidem/DMCM sensitivity is restored in only cerebellar Purkinje-Cells (PCs). b 
This is sufficient to rescue zolpidem-mediate ataxia. c In contrast with acute 
pharmacogenetic modulation, chronic 2-subunit deletion from PCs does not 
produce ataxia. Reproduced from (Wulff et al., 2007). 
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Addressing this question is possible with recent genetic technology. For instance, 
zolpidem-sensitivity can be restored selectively into brain regions, unveiling their 
specific roles in zolpidem’s effect (Sieghart, 2012). For example, Wulff et al. (2007) 
introduced 2F77 with simultaneous 2I77 knock-out selectively in cerebellar 
Purkinje-cells (PC) using the PC-active promoter L7, and triple crossing the mice 
(termed PC-2-swap). First, 2I77lox mice were crossed with L7-Cre mice. This 
knocked out 2I77-subunits in PCs. The knock-out mice were crossed with L7-2F77 
mice. The offspring have functional zolpidem-sensitive GABAA-2F77 receptors in 
PCs, and zolpidem-insensitive GABAA-2I77 receptors in the rest of the brain (Figure 
1.4. a). They were able to restore zolpidem-enhanced GABAergic IPSCs selectively 
in the PCs (Figure 1.4. a). By training PC-2-swap mice to walk on a rota-rod and 
then testing how long the mice could perform under increasing doses of zolpidem, 
they found that zolpidem enhanced inhibition onto PCs and caused ataxia, revealing 
a substrate of this particular side-effect. Using a similar approach (See Chapter 3), 
we wanted to isolate the substrates of zolpidem’s therapeutic, sleep-inducing effect. 
2-swap can also be done using AAV vectors in the adult brain. By stereotaxically 
injecting AAV containing cDNA constructs of Cre-recombinase and 2F77 into 
2I77lox mice, Sumegi et al. (2012) were able to restore zolpidem-enhanced IPSCs in 
cortical pyramidal neurons. We decided to use this approach, along with EEG 
analysis and behaviour, to investigate our sites of interest (See Chapter 3). The AAV 
mediated transgenic approach has a number of advantages. For instance, the 
genetic modification occurs in adulthood, so developmental genetic compensation is 
not a concern; and, it is quicker than using breeding strategies. Moreover, target 
sites of interest are not restricted to cell populations with a known genetic marker, so 
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anatomically defined areas, rather than genetically defined areas, can be targeted. 
But, genetic targeting can also be employed (see Methods). 
 
1.5 General anaesthetics 
 
The advent of general anaesthesia revolutionised surgery. Although they have now 
been in clinical practice for just short of 170 years, our understanding of the 
pharmacologic mechanisms only began 50 years ago (Garcia et al., 2010). The 
discovery that anaesthetics can directly modulate proteins, as initially assessed with 
the light-producing enzyme luciferase, paved a route for the protein theory of 
anaesthetic action (Franks and Lieb, 1984). Before this, people had believed that 
anaesthetic agents acted in a non-specific way by interfering with the lipid bilayer of 
cells, a comfortable notion considering how unexplainably diverse the chemicals 
were that could induce the same apparent outcome (Franks, 2006). The lipid-theory 
had become the dogma of how anaesthetics work since 1899, and was based upon 
the fact that anaesthetic potency is proportional to lipid solubility (Lugli et al., 2009). 
And while this correlation broadly fits, it turned out not to be evidence of the 
mechanisms of action. The protein theory became cemented when clinically relevant 
concentrations of the anaesthetic halothane were shown to inhibit water solubilized 
luciferase in the absence of lipids (Franks and Lieb, 1984). S(+)-isoflurane prolongs 
sleep time in rats about 50% more than R(-)-isoflurane (Dickinson et al., 2000). 
These stereoisomers also differ in their ability to confer membrane potassium 
currents at consistent membrane potentials. However, both enantiomers produce the 
same degree of lipid bilayer disruption. Therefore, the idea that anaesthetics work by 
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expanding the lipid bilayer to perturb its ability to maintain electrical potentials 
became implausible (Franks and Lieb, 1991). 
 
Now, we know that general anaesthetics work by either potentiating inhibitory 
receptors, or inhibiting excitatory receptors. The majority of general anaesthetics 
have some involvement in potentiating GABAA receptors (Garcia et al., 2010, Alkire 
et al., 2008). Such is true for isoflurane, propofol, etomitate and barbiturates which 
all enhance inhibition via GABAA receptors. However some other receptors, such as 
glycine receptors and two-pore domain potassium channels (Chau, 2010, Steinberg 
et al., 2014, Pang et al., 2009) are involved too. Isoflurane for example, causes loss 
of righting reflex (LORR) via TASK channels, which is evident in TASK1/TASK3 
knock-out mice that have reduced isoflurane induced LORR (Steinberg et al., 2014). 
In contrast with these mechanisms, the less commonly used anaesthetics xenon and 
ketamine primarily inhibit excitatory NMDA receptors (Franks, 2008). The two 
classes of general anaesthetics; the injectable type and the volatile inhalable type, 
have some similarities and differences between their mechanisms of action. 
Generally, injectable anaesthetics are used as anaesthetic induction agents. Then, 
patients are intubated and anaesthesia is maintained using volatile inhalable 
anaesthetics (Brown et al., 2010). Since the GABAA receptor has emerged as a key 
target for the majority of general anaesthetics; and because this thesis is based on 
GABAA receptors, I will focus the background information here on GABAA receptors 
(See Chapter 4) rather than the other targets. 
 
The volatile anaesthetic isoflurane binds to  and  GABAA receptor subunits. This 
includes synaptic (Harrison et al., 1993) and extrasynaptic (Jia et al., 2008) GABAA 
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receptors. Considering 221 containing GABAA receptors are the most abundant 
type, these may be the principal target isoform in isoflurane anaesthesia (Siegwart et 
al., 2002). A serine residue at position 270 of mature 1 and 2 subunits, and the 
homologous counterparts of the 3 subunit, 3S294, and the 2 subunit 2N265, 
are functionally involved in isoflurane modulation of the GABAA receptor (Jenkins et 
al., 2001, Nishikawa et al., 2002, Schofield and Harrison, 2005). Each position is on 
the second transmembrane domain (TM2) of the subunit, which forms part of the 
central pore of the receptor. However these residue positions are not critically 
involved in ion flux or GABA modulation. Isoflurane and halothane are primarily 
allosteric modulators, although they can produce a small direct channel activation in 
the absence of GABA (Nishikawa et al., 2002). 
 
Initially halothane and isoflurane were thought to have distinct binding sites because 
the 2 point mutation S270H abolished isoflurane sensitivity but conserved 
halothane sensitivity. Conversely, the point mutation 2L232F removed halothane 
sensitivity but not isoflurane sensitivity. However it later became evident that the two 
residue positions reside within in a larger binding pocket, which turned out to be a 
common site for both the anaesthetics. Jenkins et al. (2001) demonstrated this with 
point mutations of 2S270 to various different-sized amino acid residues. By using 
the largest amino acid tryptophan, to produce the mutant receptor 2S270W, they 
removed sensitivity to both isoflurane and halothane. Here, tryptophan was large 
enough to drastically affect the functional shape of the binding pocket such that 
neither of the drugs could access the site. Chloroform, on the other hand could still 
potentiate GABAergic transmission. Chloroform is smaller than isoflurane and 
halothane. So it seemed the 2S270W mutation filled a space that is required for 
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binding the larger drugs. The remaining space which chloroform could access was 
found near the 2A291 position on the TM3 region. 2A291 and the homologous 
position of 3 (A315) are also functionally involved in isoflurane modulation of the 
GABAA receptor (Krasowski et al., 1998, Schofield and Harrison, 2005). The double 
mutation 2S270W and 2A291W removed sensitivity of all three drugs (Jenkins et 
al., 2001). Furthermore, in a series of mutations of the 1S270 residue position, the 
sizes of the amino acids were proportional to isoflurane potentiation, also culminating 
in the largest amino acid tryptophan virtually abolishing sensitivity of isoflurane 
(Nishikawa et al., 2002), sevoflurane and desflurane (Nishikawa and Harrison, 
2003). Isoflurane sensitivity can also be abolished via 3A315W of the TM3 region 
and 1Y411W in TM4 (Schofield and Harrison, 2005, Jenkins et al., 2002). 
 
Contrastingly, point mutation of 2N265 attenuates does not abolish receptor 
sensitivity to isoflurane, sevoflurane or desflurane (Nishikawa et al., 2002, Nishikawa 
and Harrison, 2003). Further, there is no relationship between the size of amino acid 
residue and the magnitude of isoflurane sensitivity attenuation (Nishikawa et al., 
2002). Interestingly, however, isoflurane and halothane potency could actually be 
improved by replacing the naturally occurring asparagine with the smaller residue 
alanine (2N265A). 
 
Injectable general anaesthetics such as etomidate and propofol also rely upon 
GABAA receptor modulation, although the  subunit, especially 3, seems to more 
important in their anaesthetic action. For example 2N265S point mutant mice 
become resistant to hypothermia which is usually caused by etomidate, but they 
have normal LORR (Reynolds et al., 2003). By contrast, 3N265M point-mutant mice 
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are resistant to etomidate-mediated LORR (Forman, 2011, Jurd et al., 2003). 
Perhaps 3 selective modulators could provide safer anaesthetic induction. These 
point mutation studies provide evidence consistent with binding locations of the 
anaesthetic agents. However, considering all of these agents mentioned here have 
allosteric action, it is unclear whether the mutations actually perturb the 
conformational changes required to modulate the apparent affinity of the 
endogenous ligand – rather than the binding pocket per se. For etomidate, structural 
data using a GABAA receptor model derived from the nicotinic acetylcholine receptor 
has supported N265 being located at the binding site (Campagna-Slater and 
Weaver, 2007) However, similar work has not been done for the volatile agents. 
Perhaps this will be unravelled in the future. 
 
Although many of these general anaesthetic point-mutation studies were carried out 
over a decade ago they are still cited in recent literature (Naito et al., 2015). With our 
working knowledge of these molecular mechanisms, the next step is to understand 
how these drugs work upon different brain nuclei and circuitry to produce their 
therapeutic effects. 
 
1.6 Top-down control of wakefulness by the neocortex 
 
Sleep is vital, and so it is controlled by some of the primal phylogenetically old brain 
regions like the brain stem and hypothalamus (Saper et al., 2010). However, it goes 
without saying that wakefulness is also needed. And the regulation of sleep onset is 
augmented by the interplay between subconscious mechanisms and deliberate 
decisions and voluntary behaviours. We do not simply fall asleep the moment there 
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is the motivation to do so. Rather, we feel the need to go to sleep and subsequently 
respond by taking steps to ensure a safe and undisturbed slumber (Steenland, 
2014). These decisions come from higher order executive function in the prefrontal 
cortex. Interestingly the prefrontal cortex projects to primitive wake promoting brain 
regions like the tuberomammilary nucleus (TMN) and locus coeruleus (LC)(Gompf et 
al., 2010). Work requirements may cause people to stay up longer than they would 
prefer. Also cultural norms shape sleep periods. For instance many parts of the 
world sleep in monophasic bouts, whereas other cultures are biphasic, involving 
siestas with naps during the day (Ekirch, 2015). Further, there are some suggestions 
that the monophasic practice is a phenomenon entirely born of modern society 
(Ekirch, 2015). Also, living at different latitudes exposes different populations to 
inconsistent photoperiod lengths over the year. People living further from the equator 
must choose to maintain a relatively consistent subjective day-time throughout the 
year. This can result in a form of depression called seasonal affective disorder 
(Mersch et al., 1999). 
 
Beyond the subjective decision making of going to sleep, neocortex circuitry is 
physiologically involved in sleep-wake control (Muzur et al., 2002). There is a sleep 
active subpopulation of cortical GABAergic interneurons, characterized by neuronal 
nitric oxide synthase immuno-reactivity (Gerashchenko et al., 2008). Moreover -
oscillations, which are the hallmark of NREM sleep, are generated by the 
communication between the cortex and the thalamus. The thalamus is a sensory 
gateway to the cortex. All sensory information (except olfaction) arrives in the cortex 
via the thalamus (Sherman, 2007, Kay and Sherman, 2007). Cortico-thalamic (CT) 
projections outnumber thalamo-cortico (TC) projections (Deschênes et al., 1998). 
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CT-neurons are glutamatergic pyramidal neurons which send efferents from the 
deepest cortical layers, five and six, to excite glutamatergic TC-neurons and 
GABAergic reticular thalamic (RE) neurons (Figure 1.5.). Layer-6 CT-neurons have 
apical dendrites that extend to other layers of the cortex especially layers 2/3 and 4, 
which receive inputs from subcortical afferents (Briggs, 2010, Harris and Mrsic-
Flogel, 2013). The thalamus receives excitatory afferents from CT-neurons as well 
as ascending wake active nuclei. During waking, these inputs tonically excite TC-
neurons (Steriade et al., 1993b). This excitatory drive prevents the TC-neurons from 
entering their default oscillatory state, called burst-firing, which they assume in the 
absence of excitatory inputs (Figure 1.5.a) (Franks, 2008). One model posits that 
when TC-neurons enter this state, the functional connectivity from the thalamus to 
the cortex synchronizes the cortex to this firing pattern. As more of the cortex begins 
to fire in synchrony, the excitatory CT-inputs to the thalamus become less tonic in 
nature and facilitate more TC neurons reverting to burst-firing mode. This generates 
the high amplitude -rhythms of NREM sleep (Halassa, 2011). TC-neurons also 
projects onto the RE neurons which releases GABA back onto the TC neuron. This 
reciprocal excitatory-inhibitory activity in the thalamus becomes cyclic and network 
oscillations become consolidated. The CT-neurons can also inhibit the TC-neurons 
disynaptically by exciting the GABAergic RE neurons (Figure 1.5.b)(Deschênes et 
al., 1998). 
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Figure 1.5. Schematic of the Cortico-thalamic loop and the generation of -
oscillations. 
a CT-circuitry in waking. Descending tonic excitation from the cortex and ascending 
excitation prohibits TC-neurons from entering into burst firing. b Diminished 
excitatory drive in the thalamus enables burst-firing initiation in TC-neurons. They 
excite RT-neurons which project back to TC-neurons and produce sleep-spindles. 
TC-neurons also synchronize the cortex. Now descending excitation in the thalamus 
is less tonic, promoting more burst firing. These are the hallmarks of NREM sleep. 
Reproduced from (Franks, 2008). c Circuit diagram of cortical connectivity. Layer-5 
pyramidal neurons project to higher order thalamic areas and Layer-6 pyramidal 
neurons project to primary thalamic areas. There is also cortico-cortical connectivity. 
Reproduced from (Harris and Mrsic-Flogel, 2013). 
 
The physical connectivity is only part of the story, the frequency at which CT neurons 
fire is important; different frequencies can confer either excitation or inhibition of 
thalamic neurons. For example, Crandall et al. (2015) optogenetically stimulated 
layer-6 CT-neurons of the barrel cortex and recorded EPSPs in ventral posterior 
medial thalamic neurons. By stimulating the CT-neurons at 0.1Hz, EPSPs were 
suppressed in the thalamic neurons. However by stimulating the CT-neurons at the 
faster rate of 10Hz, EPSPs were enhanced in the thalamic neurons. Layer-6 CT-
neurons project to primary thalamic nuclei and also disynaptically inhibit pyramidal 
neurons of other cortical layers, mostly via layer-6 GABAergic interneurons (Bortone 
et al., 2014). However, they can also excite layer-5a pyramidal neurons (Kim et al., 
2014), the output layer which projects to higher order thalamus and other subcortical 
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regions such as the striatum, superior colliculus as well as other cortical layers 
(Figure 1.5.c)(Harris and Mrsic-Flogel, 2013, Feldmeyer, 2012). Interestingly,  layer 5 
of the infralimbic prefrontal cortex projects to the sleep-active ventrolateral preoptic 
(VLPO) area of the hypothalamus (Chou et al., 2002), perhaps playing a role in 
initiating sleep onset. It seems the net effect of wakefulness depends upon a delicate 
balance of timing in a complex orchestra of circuitry. 
 
-oscillations and SWA can propagate in a top-down way. Surgical dissection of the 
thalamus does not remove slow wave oscillations in the cortex (Steriade et al., 
1993a) nor does chemical blockade of action potentials of cortical afferents from the 
thalamus (Castro-Alamancos, 2000). However, slow waves do become perturbed 
when intra-cortical pathways are disconnected (Amzica and Steriade, 1995). Further, 
sleep states in local regions of the cortex can be seen during behavioural 
wakefulness (Vyazovskiy et al., 2011), perhaps foreshadowing behavioural sleep. A 
powerful example comes from work by Peñaloza-Rojas et al. (1964) who introduced 
electrodes into certain parts of the cortex in the cat. Synchronizing local areas of the 
cortex to low frequency rhythms like -oscillations and SWA were sufficient to bring 
about behavioural sleep. Conversely, high frequency rhythms evoked wakefulness. 
 
Perhaps hypnotic-drugs influence these same mechanisms. They could induce local 
sleep-like states in the cortex by prolonging IPSCs, which in turn dampens enough of 
the tonic CT excitation onto TC neurons to enable thalamic burst firing and sleep. An 
in vivo microdialysis study in cats revealed that cortical GABA levels increase over 
time spent in waking, suggesting a mechanism of homeostatic sleep pressure 
(Vanini et al., 2012). Cortical GABA levels increase during NREM sleep by about 
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40% relative to waking (Vanini et al., 2012). Interestingly, these GABA-level patterns 
are not global; suggesting the cortex is actively involved in top-down sleep 
regulation. Hypnotics like zolpidem would promote cortical GABA tone and enhance 
the effects of these physiologic increases in GABA levels. Some evidence already 
suggests that the neocortex is important in zolpidem’s action. For instance 1 and 2 
subunit containing GABAA receptors, which confer zolpidem enhanced IPSCs, are 
densely expressed throughout the neocortex (Wisden et al., 1992, Pirker et al., 2000, 
Hörtnagl et al., 2013). Moreover, fMRI data from humans has indicated that zolpidem 
activates many cortical regions (Licata et al., 2013). So called resting state networks 
may be an fMRI proxy of drug action in the brain. The paradigm involves participants 
ingesting a drug, and passively experiencing the effects without performing any 
tasks. The differences between zolpidem and placebo-baseline blood-oxygen-level-
dependent (BOLD) signal are thought to indicate activated brain loci by the drug. 
However what role the activated areas play remains speculative. Does increased 
BOLD signal at a site mean that the area is working to induce sleep, cause a side 
effect or is it incidental? A more direct measure of neuronal activity with a 
measurable behavioural outcome would be ideal and can be carried out in animal 
models (See Chapter 3). 
 
It is possible that general anaesthetics also cause LOC via action in the neocortex. 
There is evidence both for and against this view (See Chapter 4). Nevertheless, if 
the cortex is removed, anaesthetics lose their ability to affect sensory transfer in the 
thalamus (Angel, 1993), suggesting that anaesthetic-related effects in the thalamus 
are secondary to effects in the cortex. At low concentrations – just enough to induce 
LORR in rats - general anaesthetics induce a sleep-like state with -oscillations 
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(Baker et al., 2014). But at high enough concentrations, general anaesthetics induce 
reversible coma (Brown et al., 2010) and cause bi-stable quasi-periodic alternating 
bursts of cortical activity and quiet periods of low activity on EEG (Ching et al., 
2012); activity not seen in physiologic sleep. This so-called burst-suppression activity 
is theorized by some investigators to be the mechanism of anaesthetic LOC. The 
idea is: burst-suppression essentially constitutes binary oscillatory states (on or off). 
But a milieu of complex multi-faceted oscillatory states across the cortex is required 
to encode and integrate sensory information to provide consciousness. Hence, one 
hypothesis is that by removing the complexity of normal physiologic oscillatory 
activity, consciousness is lost (Alkire et al., 2008). 
 
1.7 Bottom-up control of wakefulness by the hypothalamus 
 
If sedative-hypnotic drugs which enhance neuronal inhibition cause sleep by acting 
upon specific brain circuitry it is likely that they achieve this by enhancing inhibition at 
wake-promoting brain areas. The hypothalamus contains some of these wake-
promoting regions (Saper et al., 2010). In this section, I will briefly describe what is 
known about these areas and discuss how they may be important in drug-induced 
sleep. 
 
The TMN of the posterior hypothalamus contains neurons that fire action potentials 
mainly during wakefulness (Takahashi et al., 2006, Szymusiak et al., 2007). The 
TMN contains the only neuronal source of the wake-promoting neurotransmitter 
histamine, in a population of neurons which express histamine’s synthetic enzyme - 
histidine decarboxylase (HDC) (Watanabe et al., 1984, Panula et al., 1984). HDC-
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positive neurons are a small population comprised of two sub-regions. The ventral 
part is a densely concentrated body of cells along the edge of the hypothalamus. 
The dorsal part is a more diffuse body of cells found deeper in the parenchyma of 
the hypothalamus. HDC neurons fire during waking at around 3Hz but can fire up to 
10 Hz depending on vigilant arousal (Haas and Panula, 2003, Takahashi et al., 
2006). Although the cells are located in a confined area at the bottom of the brain, 
they send axonal projections globally to the rest of the brain (Wada et al., 1991). 
Concomitantly, histamine receptors are widely expressed throughout the brain. 
Extracellular histamine in the frontal cortex is increased during wakefulness in vivo 
(Chu et al., 2004) as assessed by micro-dialysis and EEG in rats. Histamine 
receptors are G-protein coupled receptors and four types are known. H1 receptors 
(H1R) are excitatory and couple to Gq/11 which primarily activates the 
phosphoinositide secondary pathway by activating phospholipase C. H2 receptors 
(H2R) are also excitatory and couple to Gs, which activates adenylyl cyclase to 
increase cAMP production inside the cell, preceding protein kinase A activation 
(Haas and Panula, 2003, Alonso et al., 2013). H3 receptors are mainly auto-
receptors on pre-synaptic membranes; they couple to Gi/o and reduce cAMP 
formation, and act upon other downstream signal transduction as well. H4 receptors 
are mostly peripheral (Haas et al., 2008). H1R in the brain are principally involved in 
the arousal mechanisms of histamine, because H1R antagonists that cross the blood 
brain barrier are sedative. H1R knock-out mice awake less frequently from NREM 
sleep and their light-phase NREM sleep is prolonged (Huang et al., 2006). It is 
interesting that H1R knock-out confers such a mild mouse phenotype. It highlights 
how chronic knock-out studies can produce subtler effects than acute pharmacologic 
approaches. H2R knock-out mice mainly have cognitive and memory deficits 
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(Passani and Blandina, 2011). However this view may be skewed because there are 
fewer knock-out studies of H2R than H1R (Schneider et al., 2014). 
 
HDC neurons provide a beacon-like signal to the rest of the brain to sustain 
wakefulness. They receive GABAergic and galaninergic afferents from the VLPO of 
the anterior hypothalamus (Saper et al., 2010). The VLPO is a sleep active nucleus. 
cFos, which is a marker of neuronal excitability,  is turned on there during sleep and 
acute lesions cause insomnia (Lu et al., 2000). The VLPO not only sends 
GABA/galaninergic axons to the HDC neurons, but also other monoaminergic wake 
promoting areas such as the noradrenergic neurons of the LC and serotonergic 
neurons of the Raphé nucleus (RN), both located in the brainstem (Sherin et al., 
1998). Local GABAergic inhibition onto HDC neurons by the VLPO is thought to 
inhibit global histamine release to promote sleep. This mechanism is evident from 
microinjection of the GABA agonist muscimol in the posterior hypothalamus, which 
promotes sleep (Lin et al., 1989). However, while studies have previously focused on 
the VLPO, recent work has shown that neurons in the lateral preoptic area, not just 
the VLPO, become excitable during both sleep and drug-induced sedation (Zhang et 
al., 2015). 
 
HDC neurons also release GABA back onto the VLPO as well as histamine (Chou et 
al., 2002). However, in the VLPO, histamine has a net inhibitory effect. For example, 
wakefulness is promoted by histamine infusion into this sleep promoting area in cats 
(Lin et al., 1994, Strecker et al., 2002) and rats (Liu et al., 2010), suggesting 
histamine-mediated suppression of the VLPO. Moreover VLPO firing is reduced by 
histamine, but this effect is attenuated by the GABAA receptor antagonist gabazine. 
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This result led Liu et al. (2010) to conclude that histamine excites, via H1R & H2R, a 
minority population of GABAergic VLPO neurons which locally inhibit a majority 
population (~70%) of GABAergic VLPO neurons. And the larger population projects 
to wake promoting areas. This was recently confirmed using optogenetic stimulation 
of HDC-neurons which caused histamine release (but not GABA release) in the 
VLPO area (Williams et al., 2014). 
 
However, this is not the only mechanism histaminergic neurons have to cause 
inhibition; in other parts of the brain it is not the case. HDC neurons co-express 
GAD67 – a synthetic enzyme of GABA. Yu et al. (2015), in our lab, showed that in 
the neocortex and caudate-putamen (CPu), GABA released from HDC neurons 
causes inhibition to offset the excitatory effect of histamine. By optogenetically 
stimulating HDC neurons to fire at physiologically relevant frequencies (5Hz), we 
showed that the TMN promoted tonic inhibition in the neocortex and Cpu. Tonic 
inhibition is conferred by extra-synaptic GABAA receptors which classically contain 
5 or -subunits (Bright and Smart, 2013), but can also contain -subunits 
(Mortensen et al., 2010). -subunit containing GABAA receptors have relatively high 
affinity for GABA and are activated by ambient GABA from synaptic “spillover”. In 
contrast with phasic inhibition by synaptic GABAA receptors, tonic inhibition is not 
involved in temporally precise timing (Farrant and Nusser, 2005). Interestingly, in the 
Yu et al. (2015) study, H1 and H2 receptor double antagonism did not block the tonic 
inhibition, but it would have had the mechanism been via disynaptic activity (H1/H2 
receptors on GABAergic interneurons) – like in the studies by Liu et al. (2010) and 
Williams et al. (2014). However, by repeating the experiments in a vesicular GAD 
transporter (vGAT) knock-out mice - in which GABA-release from histaminergic-
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neuron terminals has been ablated - tonic inhibition on post-synaptic cells was 
removed. This revealed that GABA, released directly from HDC neurons, was 
responsible for the tonic inhibition observed earlier. Moreover, shRNA knock-down of 
vGAT mRNA, in HDC neurons, produced a hyperactive mouse phenotype during the 
dark-phase, demonstrating that GABA release from HDC neurons is physiologically 
important in sleep-wake control. 
 
The TMN (plus other wake active nuclei) and the VLPO mutually inhibit each other. 
Sitting above the VLPO nuclei, is the midline median preoptic area (MnPO) which 
also projects to wake promoting areas, and interestingly, is active in both sleep 
deprivation as well as sleep, whereas the VLPO is just active in sleep. This suggests 
the MnPO has a role in homeostatic sleep drive (Brown et al., 2012). One hypothesis 
is that the sleep active vs the wake active nuclei take dominance in a turn based 
way, and this mechanism is thought to be important for the sleep-wake cycle (Saper 
et al., 2005, Saper et al., 2001, Saper et al., 2010). Perhaps zolpidem and other BZ 
site PAMs induce sleep by enhancing this local GABAergic input at wake promoting 
regions like the histaminergic neurons of the TMN. That being said, some evidence 
suggests that histaminergic TMN neurons are actually dispensable in sleep wake 
control. Ablation of the histaminergic neurons of the TMN mostly does not change 
sleep-wake patterns in rats (Gerashchenko et al., 2004). Also, by deleting GABAA-2 
subunits from HDC-neurons, to remove fast synaptic-inhibition, Zecharia et al. (2012) 
showed GABAergic drive from the anterior hypothalamus (or anywhere else) was 
essentially unimportant in sleep-wake patterns. However, it could be that in this 
chronic knock-out study, a phenotype was masked by genetic compensation. This 
can happen when the lesioned gene is involved in something vital, such as sleep. In 
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fact, the “2-swap” study by Wulff et al. (2007), showed that removal of IPSCs from 
PCs did not produce a noticeable phenotype of motor control (Figure 1.4. c). 
However, by pharmacologically modulating IPSC in PCs with zolpidem, they did find 
a motor effect. It seems compensation happened in the knock-outs, but 
compensation was circumvented in the “2-swap” mice. 
 
Further, evidence suggests the histaminergic neurons of the TMN may be a 
substrate of isoflurane induced LOC. For example, Luo and Leung (2011) ablated 
histaminergic neurons of the TMN with orexin-saporin, which selects orexin-receptor 
bearing histamine neurons. They showed that lesioned rats had a longer return of 
righting reflex (RRR) after isoflurane anaesthesia. Perhaps, by employing short-
acting reversible effects (i.e. with drugs) any network compensation was 
circumvented, thus revealing an active role of the TMN in wake promotion. The 
authors argue that longer RRR is isoflurane specific, and not related to propofol, 
pentobarbital or ketamine anaesthesia. However, there seems to be a similar relative 
discrepancy between sham and lesioned rats’ time to RRR after pentobarbital. But 
the authors used fewer n-numbers here and the pentobarbital result was not 
significant. Had the n-numbers been consistent throughout the study, we could 
faithfully infer whether the effect was specific to isoflurane. 
 
 
51 
 
 
 
 
 
 
 
 
 
 
 
52 
 
Figure 1.6. (previous page) A 3D-image model of hypothalamic nuclei involved 
is sleep-wake control. 
This shows that most nuclei are bilateral while the MnPO is a solitary midline 
nucleus. The histaminergic neurons of the TMN and the orexinergic neurons of the 
LHA send wide-spread projections of histamine and orexins respectively and are 
active in waking. The LHA also excites the TMN. Both receive GABAergic inputs 
from the VLPO and the LHA receives further inhibition from the MnPO. However, 
these inhibitory inputs are dulled during waking because the TMN inhibits the VLPO. 
During sleep the “scales are tipped” in the other direction, and the MnPO and VLPO 
become more active to silence the TMN and LHA, which stops the release of wake-
promoting factors to the rest of the brain. This diagram is based on the “flip-flop” 
model (Saper et al., 2001, Saper et al., 2010, Saper et al., 2005). Drawn by D.S. 
Uygun. 
 
The other population of hypothalamic wake-promoting neurons is the orexin (also 
known as hypocretin) producing neurons of the lateral hypothalamus (LHA), which 
are also glutamatergic (Schöne et al., 2014). The LHA receives inputs from the 
VLPO and MnPo (Weiser and Mccarren, 2013, Uschakov et al., 2006). Orexins are 
neuropeptides of two known types, orexin A and orexin B (also called hypocretin 1 
and hypocretin 2 respectively). Both orexin peptides are cleaved from the same 
precursor molecule prepro-orexin (Hoyer and Jacobson, 2013). Orexin 1 (OX1R) and 
2 (OX2R) receptors are widespread. They are both excitatory metabotropic receptors 
coupled to Gq/11. OX1R has a higher affinity for orexin A, but OX2R binds both 
orexins equally. Orexins excite histaminergic neurons (Eriksson et al., 2001, Bayer et 
al., 2001) and the orexinergic system innervates wake-promoting nuclei such as the 
TMN and LC, therefore inhibition onto the LHA removes some of the excitatory drive 
onto these other wake promoting regions. Orexin injections in the TMN lead to 
histamine release in other parts of the brain (Huang et al., 2001, Equihua et al., 
2013). The TMN almost exclusively expresses OX2R (Marcus et al., 2001). 
Interestingly, wake promoting brain areas outside the hypothalamus preferentially 
express OXR1. Maybe, the two types of orexins are involved in different aspects of 
arousal (Mieda et al., 2013). cFos expression is suppressed in orexinergic neurons 
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after diazepam injection, so diazepam might induce sedatation by inhibiting the 
orexinergic system (Panhelainen and Korpi, 2012). Orexinergic pathways also 
appear to be involved in reward/addiction and energy homeostasis (Martin-Fardon 
and Boutrel, 2012, Mieda et al., 2013). Nevertheless, dual orexin receptor 
antagonists (DORAs) are emerging as promising new hypnotic agents (Scammell 
and Winrow, 2011, Bettica et al., 2012, Uslaner et al., 2013). 
 
1.8 Summary and aims 
 
The main focus of this project was centred on two topics. The first was whether 
hypnotic drugs can induce sleep by only acting specifically upon sleep-wake 
circuitry. The second was the role of phasic-GABAergic inhibition onto cortico-
thalamic pyramidal neurons in sleep and anaesthesia. 
 
To investigate the substrates of zolpidem-mediated sleep at the systems level, we 
introduced zolpidem-sensitivity selectively in histaminergic neurons of the TMN or 
the frontal cortex in otherwise zolpidem-insensitive mice. We achieved this in 
histaminergic neurons by injecting AAV with a Cre-dependent construct bearing the 
wild-type 2F77 subunit into HDC-Cre positive 2I77lox mice (HDC-2F77). We did it 
in the frontal cortex using an AAV construct encoding Cre and the wild-type 2F77 
subunit (FC-2F77). In both target sites, this conferred zolpidem-enhanced IPSCs in 
the transduced neurons. We found that GABAA-2F77 receptors in HDC neurons 
alone were enough to rescue the majority of zolpidem’s ability to induce sleep, 
assessed by comparison between C57BL/6 mice (positive controls) and 2I77lox mice 
(negative controls). In HDC-2F77 mice, zolpidem induced sleep to virtually the 
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same degree as giving the H1 receptor antagonist pyrilamine maleate. FC-2F77 
mice also had their sleep latency shortened by zolpidem compared with 2I77lox 
mice. The superior colliculus (SC) served as a control region. Mice with zolpidem-
sensitivity in the SC would not sleep sooner or longer than 2I77lox mice. Zolpidem 
cannot induce sleep via the SC, demonstrating that zolpidem-sleep depends on 
specific brain regions and other areas are not involved. 
 
Layer-6 pyramidal neurons of the neocortex are a main output to thalamic relay 
neurons and are expected to play a role in the generation of -oscillations. 
Consequently, we were interested in investigating the role of fast synaptic inhibition 
onto CT pyramidal neurons in LOC induced by general anaesthetics, and physiologic 
sleep-wake control. For this, we knocked-out GABAA-2 subunits in the layer-6 CT-
neurons by crossing Ntsr1-Cre mice (Gong et al., 2007, Bortone et al., 2014) with 
GABAA-2I77
lox mice (Wulff et al., 2007) to generate the novel mouse line termed L6-
2. We looked at normal sleep wake patterns as assessed by EEG and EMG, as 
well as EEG -oscillation in NREM and waking. We also looked at motor activity 
during waking. Further, we analysed dose responses of isoflurane upon LORR as 
well as time to LORR, time to RRR and brief emergence. We found this knock-out 
reduced sensitivity to isoflurane anaesthesia in the mouse but only subtly affected 
regular sleep-wake control. 
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2. METHODS 
 
2.1 Surgery 
 
Ethical permissions were made locally and with the Home office. Home Office 
Animal (Scientific Procedures) Act 1986 personal licence with modular training 
(Modules 1-4) was completed before procedures were carried out under project 
licence 70/7273. 
 
2.1.1 Mice 
 
Adult C57BL/6 inbred mice (Charles River, UK) were used as wild-type positive 
controls in all zolpidem-mediated sleep experiments. 2I77lox mice, previously 
described (Wulff et al., 2007), were used as negative controls and for AAV-CAG-Cre-
2A-2F77 microinjections in the frontal lobes of the neocortex, the Caudate Putamen 
(CPu) Globus Pallidus (GP) and Superior Colliculus (SC). HDC-2 mice, previously 
described (Zecharia et al., 2012), were microinjected with the Cre-dependant 
transgenic virus vector AAV-P-flex-rev-2F77-2A-Venus to the TMN area of the 
hypothalamus to selectively target HDC neurons. Mice were given standard chow 
and water ad libitum. All mice were kept on a reversed 12:12 hour light-dark cycle, 
so that they were in their subjective night (active period) during the real day-time 
when experiments were carried out. All experiments were carried out on mice 3-8 
months old and 19-34g. 
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2.1.2 AAV microinjections 
 
Mice were anaesthetised with isoflurane (Abbott Animal Health, UK), induced with 
~3% and maintained with ~1.5% in O2 (0.5-1 L/min) but concentrations were altered 
based on depth of anaesthesia monitoring. Mice were given buprenorphine (0.1 
mg/kg subcutaneously; Vetergesic, UK) as a pre-operative analgesic. Ocular 
lubricant (Lacrilube; Allergan, UK) was applied to their eyes. Scalp fur was clipped 
and the skin was prepared with povidone iodine surgical scrub (Vetasept; 
Animalcare, UK) Pedal, tail and palpebral reflexes were tested to assess depth of 
anaesthesia and the concentration of isoflurane was adjusted accordingly. 
Respiration was visually monitored throughout surgery and recovery. An incision was 
made in the scalp, periosteum vasculature was cleared with forceps and 
visualization of skull sutures was aided by applying 30% H2O2 (Sigma-Aldrich, UK) 
with a cotton swap. Stereotaxic surgery was performed on a Leica Angle Two 
stereotaxic frame with software for the mouse brain (Paxinos and Franklin, 2004). A 
Hamilton Microliter #701 10μl syringe with adjoining glass pipette tapered from 1 mm 
outside diameter to ~50μm diameter capillary glass tubing (Harvard apparatus, UK) 
was back-loading with mineral oil (Sigma-Aldrich, UK) and the virus mixture in the 
pipette tip. Viruses were mixed 1:1 with 20% mannitol (Merck, Germany) in PBS 
(Sigma-Aldrich, UK), which facilitates the spread of AAV infection (Mastakov et al., 
2001, Cetin et al., 2006). Injections were administered at a flow rate of 200-300 
nl/min, controlled by an electronic micro-syringe pump (nanopump, Leica, UK). 
Antibiotic Enrofloxacin (Baytril; ~0.3% v/v; Bayer, Germany) and NSAID analgesic 
carprofen (Rimadyl; 0.05% v/v; Pfizer, UK) were given postoperative in drinking 
water. 
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2.1.3 Stereotaxic coordinates for AAV injections 
 
˚ AAV-CAG-Cre-2A-GABAA-2F77 was injected unilaterally into the right CPu & 
GP with the following coordinates: 1) ML 1.60 mm AP 1.18 mm DV -3.45 mm; 
2) ML 1.60 mm AP 0.38 mm DV -3.45 mm; 3) ML 1.74 mm AP-0.34 mm DV -
3.83 mm; 4) ML 2.27 mm AP -0.82 mm, DV -3.62 mm relative to Bregma, 0.5 
l per site 
˚ AAV-P-flex-rev-2F77-2A-Venus was injected bilaterally in the TMN using the 
following coordinates: ML ± 0.92 mm, AP -2.70 mm, DV -5.34 mm relative to 
Bregma, 2 l per site 
˚ AAV-CAG-Cre-2A-GABAA-2F77 was injected bilaterally in the frontal cortex 
using the following coordinates: ML ± 1.75 mm, AP 1.87 mm, DV -1.70 mm 
relative to Bregma, 1.5 l per site 
˚ AAV-CAG-Cre-2A-GABAA-2F77 was injected bilaterally in the superior 
colliculus using the following coordinates: ML ± 1 mm, AP -3.88 mm, DV -2 
mm relative to Bregma 1l per site 
 
2.1.4 Neurologger headstages for cortical EEG/EMG recordings 
 
All the EEG data reported in this work was recorded with intracranial electrodes. 
Neurologger2 recording devices (Vyssotski et al., 2006, Anisimov et al., 2014) 
enable non-tethered recording of cortical EEG and EMG in freely moving animals. To 
record cortical EEG and EMG, electrodes were chronically implanted. Three small 
stainless steel screws (Morris Co. USA) traversing the skull into the dura mater 
served as cortical EEG electrodes: (i) in the left parietal bone AP -1.5mm and ML -
1.5mm from Bregma, (ii) in the occipital bone AP -7mm and ML 0.0mm, (iii) in the 
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frontal bone AP +1.5mm and ML +1.5mm as indicated in Figure 2.1. a. Soldered to 
these screws was Teflon insulated copper EEG wires with stripped ends. 3 EMG 
wires were secured in the trapezius muscle by feeding them each through a 
hypodermic needle inserted through the muscle tissue. The other ends of the EEG 
and EMG wires were soldered to gold plated pin connectors. The first two pins were 
soldered together and connected to screw i (ground/reference). The third pin 
connected to screw ii and the fourth pin to screw iii. Pins 5-7 each connected to 
single EMG wires, as indicated in Figure 2.1. b, which were secured in the trapezius 
muscle. Screws, EEG wires and pin connectors were secured with dental cement 
(TOC laboratory, UK) with the distal ends of the pins exposed (Figure 2.1. c), forming 
a plug for the Neurologger2 recording device. 
 
Figure 2.1. EEG and EMG electrode implantation. a A mouse scalp incision just 
prior to EEG/EMG electrode implantation. Electrode positions are marked with 
roman numerals. Stereotaxic coordinates are taken relative to Bregma (T) and 
Lamba () b EEG & EMG wires connected to a header, creating a plug for 
Neurologger2 devices. c An awake mouse with a head-stage for Neurologger2 
devices. 
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2.2 Genotyping 
 
2.2.1 2I77lox mice 
 
This mouse line was previously described by Wulff et al. (2007) To genotype, 
genomic DNA was extracted from ear or tail tissue using a pH 12 buffer made of 
25mM NaOH, 0.2mM EDTA. The tissue was incubated at >90 ˚C for 30 minutes to 
one hour before neutralizing with pH 5 40mM Tris buffer. The resulting mixture 
contained sufficient concentrations of genomic DNA to use as a template in PCR 
reactions. A DNA fragment encompassing the first loxP site upstream from exon 4 of 
the GABAA-2 subunit gene was PCR amplified using the following primer pair: 
Forward: 5′-GTCATGCTAAATATCCTACAGTGG-3′ 
Reverse: 5′-GGATAGTGCATCAGCAGACAATAG-3′ 
The thermocycler (peqSTAR, Peqlabs, Germany) was set as follows: 
94 ˚C 5 minutes hot start 
35 cycles 
 95 ˚C for 30 seconds to denature DNA 
 55 ˚C for 30 seconds to anneal primers 
 72 ˚C for 2 minutes for transcription 
72 ˚C Amplification for 5 minutes 
Reactions were stored at 4 ˚C 
 
5 μl of the reaction was run in 1% agarose gel (Figure 2.2. a) next to a ladder 
(Hyperladder 2, Bioline Ltd, UK) The presence of the loxP site provides a fragment of 
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250 bp whereas the wild-type GABAA 2-subunit produces to a fragment of 213 bp 
(Figure 2.2. a) (Wulff et al., 2007). 
 
2.2.2 HDC-2 mice 
 
These mice were first generated by Zecharia et al. (2012). Genomic DNA was 
extracted as described above and the 2I77lox genotyping protocol was performed to 
detect homozygous 2I77lox mice vs heterozygous 2I77lox/2F77 mice, for the 
experiments of this study no heterozygous mice were used. The presence of the 
Figure 2.2 Alleles of mouse 
genotypes. a Exon 4 of the 
GABAA2I77 subunit gene flanked 
with loxP sites (floxed; black 
triangles), forward and reverse 
genotyping-primer positions are 
indicated by arrows. The absence 
of a loxP site in wild-type 2F77 
alleles provide a smaller PCR 
fragment. Thus 213bp vs 250pb is a 
diagnostic result. b IRES-Cre 
expression driven by the HDC 
promoter. Forward and reverse 
genotyping-primer positions are 
indicated by arrows. The presence 
of the IRES-Cre sequence in 
genomic DNA produces a 250bp 
DNA fragment c Cre-recombinase 
expressed under the control of the 
Ntsr1 promoter. Forward and 
reverse genotyping-primer positions 
are indicated by arrows. The 
presence of the Cre sequence in 
genomic DNA produces a 300bp 
DNA fragment. 
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HDC-Cre allele produces a DNA band of 250 bp, (Figure 2.2.b; (Zecharia et al., 
2012) detected using the following primer pair: 
Forward: 5′-GTGTGGCTGCCCCTTCTGCC-3′; 
Reverse: 5′-AGCCTCACCATGGCCCCAGT-3′ 
The thermocycler was set as follows: 
95 ˚C 5 minutes hot start 
35 cycles 
 94 ˚C for 30 seconds to denature DNA 
 60 ˚C for 30 seconds to anneal primers 
 72 ˚C for 2 minutes for transcription 
72 ˚C Amplification for 5 minutes 
Reactions were stored at 4 ˚C and 5 μl was run of 1 % agarose gel (Figure 2.2. b). 
 
2.2.3 L6-2 mice 
 
To generate a novel mouse line which has 2-subunit genes deleted in layer-6 of the 
neocortex, we crossed Neurotensin receptor 1 Cre mice (Nrst1-Cre; GN220 line; 
(Gong et al., 2007) with 2I77lox mice. Nrst1-Cre mice express Cre selectively in 
layer-6 corticothalamic pyramidal neurons (Bortone et al., 2014). The Ntsr1-Cre 
allele was detected by PCR amplification of a 300 bp fragment using the following 
primer pair: 
Forward: 5’ GACGGCACGCCCCCCTTA 3’ 
Reverse: 5’ CGGCAAACGGACAGAAGCATT 3’ 
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The thermocycler was set as follows: 
94 ˚C 5 minutes hot start 
40 cycles 
 94 ˚C for 1 minute denaturing 
65 ˚C for 1 minute annealing – “Touch-down” -1˚C per cycle for 10 cycles;  
30 cycles at 55˚C 
 72 ˚C for 4 minutes transcription 
72 ˚C Amplification for 5 minutes 
Reactions were stored at 4 ˚C and 5 μl of the reaction was run on 1 % agarose gel 
(Figure 2.2. c). The Cre allele was confirmed in the F1 generation and the mice were 
backcrossed onto 2I77lox mice to produce Nrst1-Cre x 2I77lox/lox mice and the line 
was termed L6-2. In other words, we bred heterozygote Ntsr1-Cre/2I77lox/2F77 
with 2I77lox/2I77lox homozygous mice each time we needed experimental animals. 
A quarter of the offspring were Ntsr1-Cre/2I77lox/2I77lox; Cre-negative littermates 
were used as control animals. 
 
2.3 AAV transgene production 
 
2.3.1 pAAV-CAG-Cre-2A-2F77 
 
pAAV-CAG-Cre-2A-2F77, previously described by Sumegi et al. (2012) (Figure 2.3. 
a), was provided to us by Z Nusser. This transgene enables virus-mediated “2-
swap” in 2I77lox mice. The AAV transgene contains a generic strong promoter which 
is a hybrid of the cytomegalovirus (CMV) enhancer and the chicken β-actin (CBA) 
promoter and is termed CAG. The open reading frame downstream of the promoter 
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encodes Cre-recombinase followed by the 2A peptide sequence from foot and mouth 
disease virus and the WT 2F77 GABAA receptor subunit sequence. The 2A 
sequence causes codon skipping during translation, resulting in a break in the 
peptide, enabling separate translation of its two flanking sequences (Tang et al., 
2009). This provides reliably equal expression of the two peptides driven by the 
same promoter. After the “Cre-2A-2F77” cassette, the transgene contains the 
sequence for the woodchuck post-transcription regulatory element (WPRE) which 
increases transgenic protein expression in the transduced cell (Zufferey et al., 1999). 
Lastly, the transgene contains a polyadenylation signal (pA) to terminate 
transcription. The entire transgene includes the AAV2 inverted terminal repeats (ITR) 
at either end to enable integration into the host genome. 
 
2.3.2 pAAV-P-flex-hM4-mCherry 
 
After injecting AAV-Cre-2A-Venus (provided by Xiao Yu) bearing a 1191 bp 
truncated version of the murine HDC promoter (termed “P”), we found the HDC-
promoter-derived sequence paradoxically acts as a strong pan-promoter and is not 
HDC-neuron selective (Appendix 1). We wanted to engineer a construct we could 
use to selectively express the 2-subunit in HDC neurons. To use this pan promoter 
with a Cre-dependent construct, we first placed it into a plasmid that contained a 
flex-switch (enabling Cre-dependent expression (Atasoy et al., 2008)). We PCR 
amplified the promoter region from pAAV-Cre-2A-Venus with an Mlu1 recognition 
site at the 5’ end and a Sal1 recognition site at the 3’ end using the following primer 
pair: 
Forward 5’ATATATACGCGTGACCACCCCCCATGAAGTCTGTTGT 3’ 
Reverse 5’ ATATATGTCGACCTTGGATTGCTCCTCCTGGCAGACA 3’. 
 
 
64 
 
The thermocycler was set as follows: 
95 ˚C 2 minutes hot start 
30 cycles 
 95 ˚C for 1 minute to denature DNA 
 60 ˚C for 1 minute for annealing primers 
 72 ˚C for 2 minutes for transcription 
72 ˚C amplification for 10 minutes 
 
As with all of the PCR amplification reactions, we used Pfu Turbo DNA polymerase 
(Agilent Technology, United States). Using Mlu1 and Sal1 digestion, the human 
synapsin promoter was removed from a previously described transgene (Krashes et 
al., 2011; obtained from Addgene) which contains the flexed (a Cre-dependent 
construct) cDNA reading frame of the DREADD receptor hM4 fused to mCherry red 
fluorescent protein encoded in the 3’ to 5’ orientation relative to the promoter. The 
Mlu1 and Sal1 digested backbone was gel purified to discard the human synapsin 
promoter, using the Qiagen gel purification kit. The “P” sequence amplicon was then 
double digested with Mlu1 and Sal1, gel purified and ligated into the vector backbone 
using T4 quick ligase (New England Biolabs, United States). 10μl ligation reaction 
mixtures were constructed with the following insert/vector molar ratios: 3:1, 5:1 & 7:1 
to optimize the likelihood of a successful ligation. Molar ratios were calculated using 
the following formula: 𝑚0 = 𝑥 (
𝑏𝑝0
𝑏𝑝1
) 𝑚1 where m0 is the weight of insert DNA (ng), m1 
is the weight of the backbone vector (ng), bp0 is the length of the insert in base pairs, 
bp1 is the length of the backbone vector in base pairs and 𝑥 is the desired insert 
molar excess. By using an arbitrary amount of vector (50 ng) this equation produces 
the weight of insert DNA required for the desired molar ratio. Downstream of the “P” 
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sequence and the “flex-mCherry-hM4 cassette”, the transgene also contains the 
WPRE and the pA signal and the sequences are flanked by AAV ITRs. 
 
2.3.3 pAAV-flex-rev-2F77-2A-Venus 
 
pAAV-P-flex-rev-hM4-mCherry served as a vector backbone in developing this 
plasmid construct. First a unique recognition site, AvrII was introduced by site-
directed mutagenesis (Quickchange II, Stratagene, UK), between the hM4-mCherry 
sequence and the downstream lox pair using the following primer pair: 
5’ GTTGGCCATGGTGGCCCTAGGATAACTTCGTATAAAG 3’ 
5’ CTTTATACGAAGTTATCCTAGGGCCACCATGGCCAAC 3’. 
The thermocycler was set as follows:  
95 ˚C 2 minutes hot start 
16 cycles 
 95 ˚C for 1 minute denaturing 
 50 ˚C for 1 minute annealing 
 68 ˚C for 2 minutes transcription 
72 ˚C elongation for 10 minutes 
Stored at 4 ˚C 
The hM4-mCherry cassette was removed by double digestion with AscI and AvrII, 
leaving an empty flex switch, and the backbone was gel purified using the Qiagen 
gel purification kit. The 2F77-subunit reading frame was PCR-amplified from pAAV-
CAG-Cre-2A-2F77 with recognition site AvrII on the 5’ end, and both AsiSI and AscI 
on the 3’ end using the following primer pair: 
F 5’ATATATGGATCCATGACGCTGTGGATTCTG 3’ 
R 5’ ATATATGGCGCGCCGCGATCGCTTACAGATAAAGATAGGA 3’. 
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The thermocycler was set as follows:  
95 ˚C 2 minutes hot start 
30 cycles 
 95 ˚C for 1 minute denature 
 60 ˚C for 1 minute annealing 
 68 ˚C for 2 minutes transcription 
72 ˚C amplification for 10 minutes 
Stored at 4 ˚C 
 
This 2F77 sequence bearing amplicon of 1448 bp was ligated into the vector 
backbone to give a 3’ to 5’ 2-subunit coding region, relative to the promoter (i.e. 
inverted).  The resulting plasmid was double-digested with AscI and AsiSI. The 
808bp DNA fragment of 2A together with Venus was PCR amplified with the 
restriction site AsiSI on the 5’ end and AscI on the 3’ end using the following primer 
pair: 
F 5’ ATATATGCGATCGCGGCTGCTCGAGGGCAGAG 3’ 
R 5’ ATATATGGCGCGCCTTACTTGTACAGCTCGTC 3’. 
The thermocycler was set the same as during the 2-subunit reading frame 
amplification above. The PCR product “2A-Venus” was digested with Dpn-1 
restriction enzyme to destroy methylated template DNA. Antarctic phosphatase was 
used to remove the exposed phosphate groups from the vector backbone to prevent 
empty vector ligation. Enzymes in both mixtures were heat deactivated at 85˚C for ~ 
20 minutes, and nucleotides were purified using the Qiagen PCR purification kit. The 
808 bp insert was ligated into the vector backbone, again giving a coding region from 
3’ to 5’ relative to the promoter sequence (inverted). A final site directed mutagenesis 
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(Quickchange II) converted the 2-subunit’s stop codon to a furin cleavage site 
(underlined) using the following primer pair: 
F 5’ GCCCTCGAGCAAACGTTTCGCACGCAGATAAAGATAGG 3’ 
R 5’ CCTATCTTTATCTGCGTGCGAAACGTTTGCTCGAGGGC 3’. 
The thermocycler was set as follows: 
95 ˚C 2 minutes hot start 
16 cycles 
 95 ˚C for 1 minute denature 
 50 ˚C for 1 minute annealing 
 68 ˚C for 2 minutes transcription 
72 ˚C elongation for 10 minutes 
 
The final plasmid product, pAAV-flex-rev-2F77-2A-Venus, is an AAV construct that 
enables Cre-dependent expression of both the 2F77 subunit and the YFP variant 
marker protein Venus (Figure 2.3. a; Nagai et al., 2002) translated separately via 2A 
mediated codon skipping (Figure 2.3. b). The furin cleavage site introduced between 
2A and the 2-subunit mediates post-translational cleavage of an unwanted C-
terminus peptide tag of 20 amino acid residues from the 2-subunit (Figure 2.3. b; 
Luke, 2012). All modifications were confirmed by sequencing (Europhins, Germany). 
Also see Chapter 3 Results Section 3.2.3. Figure 3.3. 
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Figure 2.3. Cre-dependant expression of 2F77-subunits in histaminergic 
neurons. a Schematic of the AAV transgene designed to introduce GABAA-2F77 
subunits selectively into HDC-neurons. The subunit and reporter Venus are encoded 
inversely relative to the promoter and will not be expressed. Host-Cre in HDC 
neurons will flip the orientation (black dotted line) so that it will express and one 
homologous pair of lox sites will recombine to deactivate a single heterologous lox 
site (black dotted line), thus preventing further recombination (red dotted line; Atasoy 
et al., 2008). White triangles are Lox2272, black triangles are LoxP. b Schematic of 
translation of the AAV transgene. The 2A-peptide causes a codon skip and 
translation of the 2-subunit is complete before translation of Venus begins. The 2A 
peptide is post-translationally cleaved from the 2-subunit by furin. 
 
2.3.4 AAV production 
 
AAV-ITR flanked transgenes were packaged into AAV capsids with a mixed serotype 
of 1 & 2 and purified with heparin columns as previously described (Klugmann et al., 
2005, Murray et al., 2011, McClure et al., 2011). The following plasmids were 
needed to generate the viral vectors: 
 pF6 – Adenovirus helper plasmid, which encodes viral polymerases 
 pH21 – AAV1 helper plasmid, which contains Rep and Cap sequences 
 pRV1 – AAV2 helper plasmid, which contains Rep and Cap sequences 
 
Each AAV transgene plasmid, described in previous sections, along with these three 
AAV packaging plasmids were amplified by transforming into competent E-Coli; ice 
incubation for 30 minutes, heat shock at 42 ˚C for 40 seconds and recovery in SOC 
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or NZY broth with no antibiotic at 37˚C for one hour. Cells were then grown on 
ampicillin agar plates overnight (37˚C) and isolated colonies were used to inoculate 
amplicillin LB broth. Plasmids were extracted and purified by alkaline lysis and ion 
exchange chromatography using the Qiagen plasmid miniprep kit. 
 
HEK293 cells (maintained and cultured by R. Yustos in the lab) were transiently 
transfected with the mixture of an AAV transgene plasmid plus the helper plasmids 
using calcium chloride and 2x HeBs buffer in the following quantities: 
 
62.5 μg AAV transgene plasmid 
125 μg pF6 
31.25 μg pRV1 
31.25 μg pH21 
1650 μl 2.5 M CaCl2 
12 ml H2O 
This plasmid mixture was added to 13 ml 
(approximately half the final volume) 2x HeBs 
buffer whilst being vortexed, followed by 15 
seconds of further vigorous vortexing before being left to stand for 1 minute 45 
seconds. The total mixture was then added to the HEK293 cells and incubated at 
37˚C for 3 days. At this point the cells had time to express the AAV proteins – cells 
were dislodged into sterile warm PBS and pelleted at 800RPM. The cells were 
washed twice by re-suspending in PBS and pelleting again. Cells were re-suspended 
for lysis by 10% sodium deoxycholate and benzoase nuclease (50U/ml; 37˚C; 1 
hour). Cellular debris was pelleted by centrifugation and the virus bearing 
Figure 2.4 SDS-
polyacrylamide 
gel of principal 
viruses. Left, 
AAV-CAG-Cre-2A-
2F77. Centre,  
AAV-P-flex-2F77-
2A-Venus with 
Right ladder. This 
gel was kindly 
produced by R. 
Yustos. 
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supernatant was syringe filtered through a 45 μm diameter filter (Sartorius, 
Germany). The virus was then purified using a Hitrap heparin column (GE 
Healthcare Life Sciences, UK). 
 
The Hitrap heparin column was secured to the end of tubing that was fed through a 
peristaltic pump. The heparin column was equilibrated with 150mM NaCl, 20mM 
Tris, pH 8.0. The virus solution was added to the column and allowed to pass 
through at a rate of approximately 0.5 ml/min. The column was washed with 100mM 
NaCl followed by 200mM NaCl and finally 300mM NaCl. The AAV was eluted from 
the column with 400mM NaCl followed by 450mM NaCl and finally 500mM NaCl. All 
wash buffers and elution buffers contained 20mM pH 8.0 Tris. 
 
Lastly, the AAV virus vectors were concentrated with Amicon ultra-4 centrigal filter 
units with a molecular weight cutoff of 100000. The final concentrated virus solution 
was diluted 1:1 in sterile PBS and stored at -80˚C until use in vivo. Figure 2.4 shows 
an example 10% SDS-polyacrylamide gel with two of the principal AAV viruses used 
in this study. 
 
2.4 Histology 
 
2.4.1  Immunohistochemistry 
 
Mice were deeply anaesthetised with sodium pentobarbital (100 μl, IP; Merial, UK) 
and transcardially perfused with ~20 ml of ice cold PBS followed by ~20 ml of ice 
cold 4% paraformaldehyde (PFA) at a flow rate of 4 ml/min. Brains were submerged 
in 4% PFA overnight at 4 ˚C and then sunk in 30% sucrose solution at 4˚C. Brains 
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were frozen in crushed dry ice before slicing to a thickness of 40μm on a Leica 
microtome. Immunohistochemistry was performed on free floating sections, following 
2 hours room temperature blocking in 10% normal goat serum, 1% bovine serum 
albumin, 0.1% Triton X in PBS. The following primary antisera were used, brackets 
contain dilutions: 
- Guinea pig anti-HDC (1:300) American Research Products Ltd., USA 
- Rabbit anti-2 (1:50) R&D systems, UK 
- Rabbit anti-cre (1:1000) Novagen, Germany 
- Rabbit anti-GFP (1:1000) Stratagene, UK 
Secondary antisera with concentrations in brackets: 
- Goat anti-rabbit (1:1000) Alexo fluor 488 or 594, Life technologies, UK 
- Goat anti-guinea pig (1:1000) Alexo fluor 594, Life technologies, UK 
- Streptavidin (1:500) Alexo fluor 555 conjugate, Life technologies, UK 
Primary antisera were incubated at 4 ˚C over-night and secondary antisera were 
incubated at room temperature for 2 hours. Microscopy images were taken using 
either a Nikon eclipse 80i microscope with QCapture Pro microscopy software, Zeiss 
Cell Observer Live Cell Imaging System with Zen Pro software or Ziess LSM 510 
Inverted with Zen software. Images were processed and analysed using ImageJ and 
Adobe Photoshop. 
 
2.4.2 Quantifying transduced neurons and tissue areas 
 
To quantify neurons or brain regions infected by the virus vectors, two strategies 
were used. For the cell type selective virus that contains the Cre-dependent 
construct, the number of cells was counted. For non-cell-type-selective vectors, 
infection site areas were measured as a proportion of the entire anatomical region of 
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interest. First, cells were counted in brains from the Rosa26-lox-stop-lox-YFP/HDC-
Cre crossed Cre-reporter mouse (Figure 2.5. a). By stitching micrographs in Adobe 
Photoshop, high resolution panoramic images were generated encompassing entire 
transduced areas of coronal sections (Figure 2.5. b, top). Next, using ImageJ 
software, the contrast of stitched micrographs was increased to improve the signal to 
noise ratio and converted to binary images, i.e. black and white (Figure 2.5 b 
bottom). Binary images enable the software to automatically count particles. <15m 
and >30 m diameter outliers were not counted. Anything visually scored as an 
artefact was also manually discounted. The red rectangles in Figure 2.5. b indicate 
an example of particles too large to be counted. The red ellipses in Figure 2.5. b 
indicate an example of particles too small to be counted. The red circles in Figure 
2.5. b indicate an example of a particle that would be counted automatically, but 
removed from the data having been visually identified as something other than a 
neuron, in this case it is a microglial cell. 
 
Figure 2.5 Method for quantifying the extent of 2F77 rescue in HDC neurons. 
a, alleles for generating an HDC-Cre reporter line. Mice in which Cre is expressed 
under the control of the HDC promoter were crossed with a ROSA-lox-STOP-lox-
YFP mouse. In the offspring, Cre deactivates the stop-cassette to liberate YFP 
expression (Zecharia et al., 2012).b Top, A representative micrograph from an HDC-
YFP mouse hypothalamus. Bottom, binary conversion for automatic particle 
counting. Artefacts which were not counted are indicated in red. c, Three cell counts. 
An extrapolated estimate used to verify the accuracy of an exhaustive observed 
count of the HDC-2F77 neurons and an extrapolated count of an HDC-YFP reporter 
brain. Dr Xiao Yu kindly provided the micrograph in panel b, top. 
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Coronal TMN area sections were imaged exhaustively and each section was 
ascribed to an atlas A-P coordinate. To increase confidence that neurons were not 
counted twice, should any given neuron be represented in neighbouring slices, an 
extrapolated count was also performed. Here, rather than counting the neurons 
exhaustively, one section per atlas A-P coordinate was analysed, constituting seven 
coronal sections per brain. The sum of cells from these sections was divided by 
seven and then multiplied by 18, this being the number of sections needed, given the 
40μm thickness, to cover the whole TMN area of approximately 700μm. The mean 
number of neurons from AAV transduced brains was compared to an extrapolated 
count from a single HDC-Rosa-YFP mouse brain (Figure 2.5 c). Because the 
exhaustive count was considered accurate and also less exclusive, three of the four 
brains of mice used in behavioural assays were analysed in this way, the fourth brain 
was used to collect voltage clamp electrophysiological data. Other brain areas were 
targeted in a non-Cre-dependent way. For these, proportions of the target 
anatomical regions were estimated. Micrographs of the entire brain region were 
acquired. Using ImageJ, areas of infection sites were measured. Percentage areas 
of transduced tissue of target brain regions of interest were calculated and values 
were presented as a percentage per A-P coordinate. 
 
2.5 Drugs 
 
Zolpidem tartrate. Zolpidem, chemical name: N,N,6-Trimethyl-2-(4-
methylphenyl)imidazo[1.2-a]pyridine-3-acetamide (Tocris Biosciences, UK) was 
dissolved in an equimolar solution of tartaric acid (BDH Chemicals Ltd., England) in 
0.9% (w/v) saline. 
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Mepyramine maleate (Pyrilamine), chemical name: 2-((2-(Dimethylamino)ethyl)(p-
methoxybenzyl)amino)-pyridine maleate (Tocris Biosciences, UK) was dissolved in 
0.9% (w/v) Saline. 
 
Isoflurane, chemical name:  2-Chloro-2(difluoromethoxy)-1,1,1,trifluoro-ethane 
(Abbott Animal Health, UK) was suspended in pure O2 (BOC, UK). 
 
2.6 Behaviour 
 
2.6.1 EEG recordings and sleep scoring 
 
Cortical EEG signals were recorded on Neurologger2 devices and data were 
downloaded afterwards offline. All data were sampled at 200Hz. Spike2 software 
(Cambridge Electronic Design, Cambridge, UK) was used to visualize and filter 
waveforms. EEG signals were high-pass filtered at >0.5 Hz, EMG data was band-
pass filtered between 5 & 45 Hz. Vigilance states Wake, NREM and REM were 
automatically scored using a script based on sleep scoring criteria described by 
Costa-Miserachs et al. (2003), and the results were verified manually. The scoring 
criteria were as follows: 
 
Wake: High EMG signal, low  signal, high ratio 
NREM: Low EMG signal, high  signal, low  ratio 
REM: Low EMG signal, low  signal, high ratio 
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2.6.2 Turning behaviour 
 
2I77lox mice were video recorded (Logitec webcam and Debute Capture Software) 
in a 12cm diameter cylinder. Mice were given zolpidem (10 mg/kg) and matched 
volume saline; first before and again one month after unilateral AAV-CAG-Cre-2A-
2F77 injection to the CPu and GP. Thus each condition provided a repeated 
measure. Left and right turns were scored post-hoc from video footage. Turns were 
counted as any non-linear ambulatory movement. In other words the mouse had to 
walk in a circle. Grooming and head turns were not counted. Single turns were 
counted as anything up to 360°, anything more than that, more turns were scored 
correspondingly. Figure 2.6 shows an example of a single clockwise turn.  
Figure 2.6. Turning Behaviour. Still images of a single turn. 
 
2.6.3 Home cage EEG/EMG recordings 
 
During the zolpidem experiments, EEG recordings were performed in home cages 
during the dark phase when mice are more active. Experiments were carried out as 
close to four hours after “lights off” as possible, and usually between 2 and 6 hours 
after “lights-off”. Mice were allowed to acclimatize to “mock” neurologgers, which are 
the same size and weight as the Neurologger2 recording devices. The mice were 
first allowed to acclimatize to the lab before Neurologgers were fitted and drugs were 
administered. A period of 15 minutes was allowed after switching “mock” to real 
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Neurologgers before drugs were given. Mice were also allowed to stay in the home 
cage between all handling procedures to minimize stress. EEG & EMG was then 
recorded over 2 hours. 
 
2.6.4 Open field activity monitor experiments 
 
Mice were placed in an open field (27.5 cm2). The open field apparatus automatically 
counts and tracks X & Y coordinates using infrared beams (16 by 16) which are 
broken by the animal’s movements. Parameters include distance travelled, 
ambulatory episodes, time moving and time resting. Thigmotaxis was assessed by 
using coordinate positions in the centre and periphery of the open area. Heat maps 
were created in OriginPro with matrices generated in Matlab in which the number of 
visits to a coordinate was plotted into 16 by 16 bins each representing the infrared 
beam locations. Elly Steinberg kindly performed the Matlab work. 
 
2.7 L6-2 isoflurane LORR 
 
2.7.1 Dose response experiments  
 
L6-2 mice and Cre-negative littermates were placed in a glass cylinder (~ 800 ml) 
with inlet and outlet tubing for gas flow (Figure 2.7). In a pilot experiment to 
determine a starting concentration of isoflurane, mice were subjected to pure O2 for 
five minute before isoflurane was introduced at an initial concentration of 0.4% which 
was assumed to be too low to induce LORR. Concentrations were increased by 
0.2% every five minutes. O2 and isoflurane were administered at flow rate of 2 L/min. 
It was clear from this initial work that no mouse lost their righting reflex at 0.8% but 
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all mice lost it by 1.2%. In subsequent dose response experiments, all mice were 
subjected to pure O2 for five minutes and isoflurane was introduced at an initial 
concentration of 0.6%. Concentrations were increased by increments of 0.1% every 
five minutes to provide better resolution of the effective doses. Concentration and 
flow rate was controlled using a Datex Ohmeda Aestiva anaethetic machine with a 
Datex Ohmeda IsoTec 5 isoflurane anaesthesic vaporizer (Integris Equipment, 
United States). At the end of each five minute interval, the cylinder was gently 
rotated manually to test the righting reflex of the mouse. At sufficient concentrations, 
each mouse was rolled on to its back and LORR was recorded when the mouse 
could not return to prone position with all paws on the inside surface of the cylinder, 
within 30 seconds. The session was stopped after 1.4% isoflurane concentration had 
been reached. Isoflurane was passively scavenged using a charcoal filled "flusorber" 
anaesthetic scavenger (Harvard apparatus, UK).  
 
 
2.7.2 LORR, brief emergence & RRR experiments 
 
The same individual mice were used to assess time to LORR and time to RRR. 
These experiments were conducted at least one week after the dose response 
experiments and the same apparatus were used. Mice were placed into the cylinder 
and given 1.2% isoflurane in O2 (2 L/min). Mice were visually observed. When mice 
Figure 2.7 Schematic of LORR 
by volatile anaesthetic 
isoflurane experiments. Curved 
arrow shows the movement of 
the cylinder to roll the mouse 
onto its back. Straight arrows 
show anaesthetic gas inlet and 
outlet. 
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became immobile, their righting reflex was tested by rolling them onto their backs by 
manually rotating the cylinder gently. If mice could right themselves to prone 
position, they were immediately tipped again. When mice could not right themselves 
within 30 seconds they were scored as having lost their righting reflex. The time 
recorded was the beginning of the 30 second period. Mice were then kept 
anaesthetized for 10 minutes. Occasionally mice would briefly regain muscle tone 
and unsuccessfully attempt to right themselves, as per scale three of the righting 
reflex criteria for scoring depth of anaesthesia (Devor and Zalkind, 2001). These 
events were recorded and termed brief emergence. At the end of the ten minute 
period, mice remained in the chamber with pure O2 (2 L/min). RRR was recorded 
when they could right themselves to prone position with all four paws on the inside 
surface of the chamber. All the experiments were conducted with normal ambient 
indoor light in quiet conditions. 
 
2.8 Brain slice electrophysiology 
 
Voltage-clamp recordings of HDC-2F77 neurones were carried out by Drs Anna 
Zecharia and Zhiwen Ye, and recordings of cortical pyramidal FC-2F77 neurons 
were carried out by Dr Zhiwen Ye. The methods were consistent with Yu et al., 
(2015). 
 
2.9 Statistical analysis 
 
Most of the behavioural experiment designs involved between-subjects and within-
subjects factors. For this, Mixed-design ANOVA (zolpidem experiments) or un-paired 
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t-tests (L6-2 experiments), where appropriate, were used to test differences 
between collated bins of EEG power. Mixed-design ANOVA with either Bonferroni’s 
or Tukey’s post hoc tests were used in all comparisons of behavioural data and EEG 
power spectra. The only experiments with more than two levels in the within-subjects 
factor were the HDC2F77 experiments, for this Mauchley’s test was used to 
choose the appropriate ANOVA test and sphericity was never violated. Shapiro-
Wilk’s test was used to confirm normal distribution to aid choosing parametric tests. 
Paired sample t-tests were used to compare the decay times of IPSCs. A p-value of 
0.05 was adopted to reject null hypotheses. All statistical analyses were performed in 
OriginPro8.6 or Excel. Dose response curves of isoflurane were performed in Matlab 
using a script based on Waud’s biological assay on quantal analysis (Waud, 1972) 
provided by Dr Chris Edge. Curves were fitted using Hill’s function with parameters 
manually adjusted to Waud’s ED50 and slope in OriginPro 8.6.  
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3. Mapping the neuroanatomical substrates of zolpidem-
mediated sleep reveals histaminergic neurons and the 
frontal cortex are key targets 
 
3.1 Chapter Introduction 
 
The sedative-hypnotic zolpidem, a positive allosteric modulator (PAM) of the GABAA 
receptor, which binds to the benzodiazepine (BZ) site, is a mainstay therapeutic of 
insomnia. Treating insomnia is instrumental to public health as prevalence is as high 
as 30% (Woznica et al., 2014). Zolpidem is commonly prescribed because it has 
fewer rebound effects than BZs (Randall et al., 2012) and generally does not cause 
any next day effects (Roth et al., 1995). It also provides effective relief from insomnia 
for  prolonged periods of regular use (Randall et al., 2012). However there have 
been problems with amnesic, delirious side-effects which pose problems for patients 
(Toner et al., 2000, Inagaki et al., 2010, Tsai et al., 2007). Consequently, 
understanding zolpidem’s action in the brain is important. Because zolpidem binds 
1-3,,2 containing GABAA receptors, which are widespread (Wisden et al., 1992), 
it acts virtually everywhere in the brain. We do not know if zolpidem causes sleep by 
enhancing GABAergic inhibition throughout the entire brain, or if the therapeutic 
sleep-inducing property depends upon specific brain circuitry. 
 
Point-mutant studies of GABAA receptor -subunits have demonstrated that different 
behavioural attributes of PAMs, like zolpidem, each depend upon particular GABAA 
receptor sub-units. For example, 1H101R abolishes diazepam motor-sedation and 
attenuates zolpidem motor-sedation (Crestani et al., 2000). Conversely, 2H101R 
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abolishes diazepam anxiolysis but does not affect motor-sedation. The homologous 
point-mutation 3H126R also retains diazepam sedation but attenuates 
myorelaxation (Rudolph and Knoflach, 2011). Each subunit-type has its own 
expression pattern throughout the brain. So, each type may communicate different 
behaviours due to where they are situated anatomically. 
 
2I77 mice are devoid of zolpidem-sensitivity. Zolpidem does not prolong their IPSCs 
or sedate them (Cope et al., 2004, Cope et al., 2005). Interestingly, zolpidem-
sensitivity can be restored selectively in brain regions, revealing their specific roles in 
zolpidem’s effect. For example, Wulff et al. (2007) introduced 2F77 with 
simultaneous 2I77 knock-out (termed “2-swap”) selectively in cerebellar Purkinje-
cells (PC). Zolpidem enhanced inhibition onto PCs to cause ataxia, revealing a 
substrate of this side-effect of zolpidem. 
 
Using a similar approach, we wanted to isolate the therapeutic effect of zolpidem i.e 
sleep induction. To investigate the neuroanatomical substrates of zolpidem-mediated 
sleep, we injected a Cre-dependent AAV construct encoding the GABAA-2F77 
subunit into the TMN area of HDC-2 mice – which have Cre in their histaminergic 
neurons. We were able to selectively restore zolpidem sensitivity in histaminergic 
neurons. This conferred zolpidem-enhanced IPSCs in HDC neurons. By comparing 
with wild-type C57BL/6 mice and zolpidem insensitive 2I77lox mice, we found that 
GABAA-2F77 receptors in HDC neurons alone were enough to rescue the majority 
of zolpidem’s ability to induce and prolong sleep. HDC-2F77 mice fell asleep faster 
and stayed asleep longer when they were given zolpidem, and the response was 
similar to that of H1 receptor antagonist pyrilamine maleate. Next we wanted to look 
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at the role of the frontal neocortex in zolpidem-mediated sleep. By introducing AAV 
constructs containing the cDNA of Cre and GABAA-2F77 receptors into 2I77
lox 
mice, we were able to simultaneously knock-out GABAA-2I77 receptors, while 
introducing GABAA-2F77 across all layers in frontal cortex (FC-2F77), including 
both motor and pre-motor areas. This also achieved zolpidem-enhanced IPSCs in 
cortical pyramidal neurons. FC-2F77 mice also fell asleep more rapidly after 
zolpidem compared with 2I77lox mice. By targeting a negative control area – the 
superior colliculus – we show that HDC neurons and the frontal cortex are both 
substrates involved in zolpidem-mediated sleep. 
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3.2 Results 
3.2.1 EEG analysis confirms 2I77lox mice are devoid of zolpidem-sensitivity 
 
2I77lox mice have previously been shown as completely devoid of any zolpidem 
sensitivity (Cope et al., 2004, Wulff et al., 2007). However, effects on EEG were 
never reported in the past. Because we wanted to introduce zolpidem sensitivity in 
specific areas, we first needed to make sure we were working on a background of no 
zolpidem sensitivity. Also, because EEG & EMG provide our proxy of sleep/wake 
states, confirming a zolpidem-void EEG background signal was crucial. To confirm 
that EEG was left unaltered by zolpidem in 2I77lox mice, we compared EEG power 
profiles at 1, 5, 10 and 20 mg/kg zolpidem relative to saline, and compared the 
results to C57BL/6 mice which have GABA-2F77 receptors and normal zolpidem 
sensitivity (Appendix 2). Zolpidem has a half-life of 20 minutes (Benavides et al., 
1988) and induces sleep in about 2 to 4 minutes. We compared EEG power spectra 
for 15 minutes starting 2 minutes after drug administration. 1mg/kg zolpidem caused 
sedation in C57BL/6 mice but not sleep. 5mg/kg zolpidem was the lowest dose to 
initiate short onset sleep in C57BL/6 mice. At 5mg/kg and higher, zolpidem did not 
shorten sleep latency in 2I77lox mice. Figure 3.1. a shows representative hynogram 
(but see Appendix 3), demonstrating short sleep latency by zolpidem in a C57BL/6 
mouse, contrasting with non-induced sleep after an injection of saline. Figure 3.1. b, 
however, shows zolpidem does not shorten sleep latency in 2I77lox mice relative to 
saline (Figure 3.1. b) The EEG power spectrum was similar between 5mg/kg and 
higher doses (Appendix 2), although 20mg/kg produced a small enhancement of -
oscillations in the 2I77lox mice (Appendix 2). So we used 5mg/kg zolpidem in the 
other zolpidem-sleep experiments. 
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Figure 3.1. Zolpidem does not induce sleep in 2I77lox mice: EEG analysis. 
a & b, Hypnograms after zolpidem (5mg/kg) or saline (matched volume) i.p. 
injections in a C57BL/6 (2F77) mouse (a) or 2I77lox mouse (b).  All traces are 
aligned relative to the time of drug or saline injection (arrow) and followed for the first 
45 mins after injection. The vigilance states of NREM (N), REM (R) and wake (W) 
are shown as line blocks, together with a segment of the  ratio below these, and 
examples of primary aligned EMG and EEG data. The  component of the EEG is 
also shown in a separate trace. EEG, electroencephalogram; EMG, electromyogram; 
N, NREM sleep; R, REM sleep; W, wake;  c, Normalized EEG power spectrum of 
C57BL/6 (2F77) mice (n = 6) after saline i.p. injection (black) and zolpidem i.p. (5 
mg/kg; red). d, Normalized EEG power spectrum of 2I77lox mice (n = 6) after saline 
i.p. injection (black) and zolpidem i.p. (5 mg/kg; red). Flat horizontal bars indicate 
significance ***p < 0.001, n.s., not significantly different,  Mixed-design AVOVA with 
Bonferroni’s correction. 
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~1~6 Hz EEG power 
 
In C57BL/6 mice (n = 6), administration of 5mg/kg zolpidem (Red, Figure 3.1. c) 
caused the power of frequencies between ~1 Hz and ~6 Hz (indicated by the 
horizontal bar near the x axis in Figure 3.1. c) to increase by 175% compared to 
saline control injections (Black, Figure 3.1. c). Mixed-design ANOVA confirmed a 
significant interaction between the drug (saline or zolpidem) and the strain of mouse 
(C57BL/6 vs 2I77lox): F (1, 154) = 15.171, p = .0001. Bonferroni’s post-hoc test 
confirmed the differences were between saline and zolpidem in C57BL/6 mice (t 
(154) = 6.47, p = 7 × 10−9 ), and between C57BL/6 mice and 2I77lox mice with 
zolpidem (t (154) = 5.262, p = 3 × 10−6). The same frequencies were unchanged 
between saline and zolpidem in 2I77lox mice (n = 6; Figure 3.1. d). As expected, 
saline produced no significant difference between the mouse strains. Zolpidem 
caused C57BL/6 mice to fall asleep in under 3 and a half minutes (mean) whereas 
2I77lox mice did not fall asleep for approximately 40 minutes. 
 
~7~9.5 Hz EEG power 
 
In C57BL/6 mice, 5kg/kg zolpidem caused a 34% decrease in frequency power 
between ~7 and ~ 9.5 Hz. There was a small non-significant increase of 16% in 
these frequencies in the 2I77lox strain. Mixed design ANOVA confirmed a significant 
interaction between the drug factor and the mouse stain factor F (1, 82) = 18.933, p 
= .00004. Similar to above, Bonferroni’s post hoc test showed the significant 
differences to be between saline and zolpidem for C57BL/6 mice (Figure 3.1. c) (t 
(82) = 4.4, p = .0002) and between C57BL/6 mice and 2I77lox mice with zolpidem (t 
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(82) = 3.84, p = .001). However, there was no significant difference between saline 
and zolpidem for 2I77lox mice (Figure 3.1. d) or between the two strains with saline. 
 
~12~20 Hz EEG power 
 
Compared with a saline vehicle control, 5mg/kg zolpidem caused a 101% increase in 
power frequencies between ~12 and ~20 Hz in C57/bl6 mice (mixed-design ANOVA, 
F (1, 262) = 89.835, p = 2 × 10−18, Bonferroni’s post hoc, t (262) = 13.508, p = 
4 × 10−31) (Figure 3.1. c). As expected, there was no significant difference between 
saline and zolpidem in the 2I77lox strain (Figure 3.1. d). 
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3.2.2 AAV-mediated “2-swap” is powerful enough to use in behavioural 
assays 
 
Figure 3.2. “2-swap” in the caudate-putamen and globus pallidus. a Mouse 
allele (top) and the AAV construct (bottom) used to cause local “2-swap”. b 
Schematic diagram of AAV microinjection in a 2I77lox mouse brain - unilateral 
injection into caudate-putamen (CPu) and globus pallidus (GP). c AAV mediated Cre 
Recombinase immunohistochemistry in the target locus. LV; lateral ventricle, CTX; 
cortex d Turn ratios, deviations from one illustrate a directional turn bias – the 
behavioural proxy of unilateral inhibition by drug administration. *p < 0.05, Tukey’s 
post hoc test. n = 3. 
 
Once we knew zolpidem did not have an EEG profile in 2I77lox mice, we wanted to 
test the “2-swap” method was powerful enough to use for behavioural experiments, 
which would abate concerns about false negatives in later experiments. We chose a 
robust behavioural assay – turning behaviour. We injected AAV-Cre-2A-2F77 
(Figure 3.2. a) unilaterally in the caudate-putamen (CPu) and globus pallidus (GP) to 
generate CPu-2F77 mice (Figure 3.2. b). Target site expression was assessed 
using anti-cre immunohistochemistry (Figure 3.2. c). Mice were injected IP with 
saline and zolpidem and placed in an upright cylinder. The number of full turns were 
counted and calculated as ratios (left verses right turns) to assess if unilateral 
zolpidem action at the CPu and GP would lead to a one sided turn bias. Before mice 
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were given zolpidem sensitivity via stereotaxic AAV injection, they showed no 
preference to turn either left or right whether they were given saline or zolpidem 
(Figure 3.2. d, black). However, after unilateral AAV mediated CPu-2F77 rescue, 
zolpidem caused a tendency for mice to make ipsilateral turns (Figure 3.2. d, red) 
(repeated-measure ANOVA with Tukey’s post hoc comparison t (2) = 6.36, p = .046), 
whereas saline did not cause any significant change. Once we had confirmed that 
AAV mediated introduction of 2F77-subunits would provide behavioural results we 
focused on using it to investigate zolpdidem’s propensity to induce sleep. 
 
3.2.3 HDC neurons are sufficient targets in zolpidem mediated sleep. 
 
We wanted to use a “Cre-dependent” strategy to select and isolate histaminergic 
neurons. For this, a novel AAV construct was required, we needed a Cre-dependent 
AAV vector that would selectively introduce zolpidem-sensitive 2F77 containing 
GABAA receptors onto HDC-positive neurons of HDC2I77 mice – which express 
Cre specifically in HDC-neurons. I designed and developed this AAV construct using 
cDNA from various plasmids that we were using in other experiments in the lab. 
First, I PCR amplified the 2F77-gene, flanked with restriction sites 5’ AvrII and 3’ 
AsiSI+AscI (Figure 3.3. a) for orientation-directed ligation, the double restriction site 
at the 3’ end enables the introduction of a subsequent cDNA fragment. I then PCR 
amplified a 808 bp “2A-Venus” cassette, flanked with restriction sites 5’ AscSI and 3’ 
AscI (Figure 3.3 b). I introduced the two PCR amplified fragments into a 5496 bp 
plasmid backbone within a flex-switch (Atasoy et al., 2008), encoded in the inverse 
orientation relative to the promoter (Figure 3.3. c). Into this backbone, I had 
previously introduced a 1191 bp “pan-promoter” derived from the murine HDC-
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promoter sequence (P; Figure 3.3. b,c). Finally, a furin-cleavage site sequence 
(Figure 3.3. d) was introduced between the 2F77-sequence and the 2A sequence 
by site-directed mutagenesis (See Methods Section 2.3.1.). 
 
Previously, Zecharia et al. (2012) in our lab, generated and studied HDC-2I77 
mice, which are mice with a deletion of the 2I77 subunit from histaminergic neurons 
in the TMN, obtained by crossing HDC-Cre and 2I77lox mice (Zecharia et al., 2012). 
The histaminergic neurons of these HDC-2I77 mice lack IPSCs (Zecharia et al., 
2012). Because the HDC-2I77 mice still had Cre recombinase expressed in their 
histaminergic neurons, we could implement a “restorative genetics” strategy and put 
Figure 3.3 Plasmid maps of the 
AAV transgene constructs 
required to rescue zolpidem-
sensitivity in histaminergic HDC-
neurons. a AAV construct used for 
inducing local acute “2-swap” in 
2I77lox mice (Sumegi et al., 2012). A 
fragment of 1448bp including 2-
subunit sequence was PCR amplified 
to ligate into other AAV constructs b 
AAV construct used for virus-
mediated Cre-lox knock-out bearing a 
strong pan promoter used for AAV 
vectors specifically designed to 
promote expression in HDC neurons 
(Appendix 1) plus 2A-Venus. c AAV 
construct purified to serve as a 
backbone (5496bp) for creating a 
Cre-dependent vector d Cre-
dependent vector designed to 
introduce zolpidem-sensitive 2F77- 
subunits selectively in histaminergic 
neurons and tag them with Venus 
protein. ITR; inverted terminal 
repeats, WPRE; woodchuck post-
transcriptional regulatory element, 
AmpR; ampicillin resistance gene. 
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the 2-subunit back into the neurons from which it was deleted. We introduced the 
zolpidem-sensitive 2F77 subunit into the histaminergic neurons of HDC-2I77 mice 
using the Cre recombinase-flex switch-dependent transgene described above 
(Atasoy et al., 2008), flex-rev-2F77-2A-Venus (Figure 3.3. d), packaged into AAV 
capsids (Figure 3.4. a). This AAV-flex-rev-2F77-2A-Venus was bilaterally injected 
into the ventral TMN area of adult HDC-2I77 mice to generate HDC-2F77 mice 
(Figure 3.4. b). The flex switch in the AAV transgene ensured that 2F77 expression 
was restricted to Cre-positive neurons (Figure 3.4. b,c). These mice had bilateral 
expression of the 2F77-2A-Venus transgene in their TMN area, confined to HDC 
neurons in the ventral parts of the TMN (Figure 3.4. b), in an approx. 700 μm anterior 
to posterior segment (Figure 3.4. d). The mean number of AAV transduced neurons 
in HDC-2F77 brains, as assessed by Venus expression, was compared with a count 
performed on a brain from an HDC-Cre x Rosa-YFP reporter mouse cross. We found 
HDC-Cre x Rosa-YFP mice had about 8000 neurons in which the HDC promoter 
was active in the TMN area (see Methods Section 2.4.2, Figure 2.5.). This could be 
an overestimate because some of the Rosa-YFP expression could originate from the 
HDC-Cre gene turning on and off during development. In the adult HDC-2F77 mice, 
where Venus expression can only be seen if the HDC-Cre gene is active in the adult, 
about 7000 Venus-positive cells could be detected. This number will be an 
underestimate since it cannot be expected that all histaminergic neurons in HDC-2 
mice would be transduced by the AAV-flex-rev-2F77-2A-Venus virus (see below). 
On the other hand, counts of cells immunoreactive for histamine estimated that there 
were 2500-3500 such neurons in the mouse hypothalamus (Parmentier et al., 2002), 
and 3800 in the rat determined by staining with HDC antibodies (Ericson et al., 
1987). Given the difference in sensitivity between the genetic and primary 
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immunoreactive detection methods, our estimate of histaminergic neuronal number 
is roughly in the same range. The extent of AAV transduction in HDC-2F77 mice 
was also ascertained by whole-cell voltage-clamp in neurons recorded in acute 
slices made from the posterior hypothalamus (Performed by Drs Zhiwen Ye & Anna 
Zecharia). In the ventral TMN region we found that 10 out of 16 neurons (62.5 %) 
had restored IPSCs that looked like IPSCs on C57BL/6 neurons (e.g. Figure 3.4. e). 
Of these 16 cells, the remaining 6 still had small events that looked like those in the 
original HDC-2 knockout cells (Zecharia et al., 2012), and no IPSCs were restored 
(not shown). Presumably these six neurons had not been transduced by the AAV-
flex-rev-2F77-2A-Venus virus. We confirmed that the HDC-2F77 histaminergic 
neurons with rescued IPSCs also had restored zolpidem-sensitivity: 10 μM zolpidem 
applied to C57BL/6 (2F77) histaminergic cells slowed the IPSC decay by 48% 
(mean ± 8.4; n = 6 cells, t-test, p = 0.0008; Figure 3.4. e,f); by contrast, 10 μM 
zolpidem applied to 2I77lox histaminergic neurons had no effect on the IPSC decay 
(n = 5 cells, t-test p = 0.27) (Figure 3.4. e,f); but 10 μM zolpidem applied to HDC-
2F77 neurons slowed the IPSC decay by 46% (mean ± 7.3, n = 6 cells, t-test, p = 
0.001) (Figure 3.4. e,f), the same magnitude of response obtained by applying 
zolpidem to C57BL/6 histaminergic neurons (Figure 3.4. e,f). 
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Figure 3.4. (previous page) HDC-2F77 mice have histaminergic neurons 
selectively sensitive to zolpidem. 
a, The  alleles HDC-Cre and 2I77lox in HDC-2 mice, and the AAV flex-switch 
transgene construct AAV-flex-rev-2F77-2A-Venus used to selectively label (Venus) 
and introduce zolpidem-sensitivity (2F77) in HDC-2 neurons to generate HDC-
2F77 mice. Open triangles, loxP sites; shaded triangles, lox2272 sites. ITR, inverted 
terminal repeats; P, pan-promoter (hdc gene promoter fragment); b, Schematic of 
AAV microinjection into the HDC-2 mouse brain. TMN, tuberomamillary nucleus; c, 
Histaminergic neurons labelled by Cre-dependent activation of the AAV-flex-rev-
2F77-2A-Venus transgene, detected by immunohistochemistry with GFP antisera; 
d, Number of Venus-labelled neurons  along the rostral-caudal axis of the posterior 
hypothalamus, detected by GFP immunohistochemistry; e, peak-normalized IPSCs 
on histaminergic neurons in acute brain slices from the posterior hypothalamus of 
C57BL/6 (2F77), 2I77lox and HDC-2F77  mice before (black) and after 10 M 
zolpidem (red) application. f, Weighted decay times before and after zolpidem 
application for the different groups of mice. ***p < 0.001 Drs Zhiwen Ye & Anna 
Zecharia kindly collected and analysed the voltage-clamp data. 
 
At the behavioural level, we found HDC neurons constitute an important substrate in 
zolpidem mediated sleep, as shown by a significant interaction between mouse type 
and drug (mixed-design ANOVA F (4, 18) = 4.547, p = 0.01). Compared with saline, 
zolpidem decreased sleep latency by 75% (Figure 3.5. a) in HDC-2F77 mice (n = 4) 
(mixed-design ANOVA, Tukey’s post hoc comparison t (18) = 6.308, p < .0008). We 
postulated that zolpidem caused this effect by silencing HDC neurons, and in turn, 
inhibiting the release of histamine to the rest of the brain. To support this notion we 
administered H1 receptor antagonist pyrilamine maleate to the same group of HDC-
2F77 mice, which decreased sleep latency to essentially the same degree (Figure 
3.5. a). Compared with saline, pyrilamine shortened sleep latency by 73% (mixed-
design ANOVA, Tukey’s post hoc comparison t (18) = 6.104 p = .001). In C57BL/6 
mice (n = 4) harbouring ubiquitous 2F77 GABAA receptors, zolpidem significantly 
shortened sleep latency (Figure 3.5. a) by 91%, compared with saline (mixed-design 
ANOVA, Tukey’s post hoc comparison t (18) = 4.707, p = .00995). However the 
sleep latency in C57BL/6 mice after zolpidem was not significantly shorter than that 
 
 
94 
 
of HDC-2F77 mice in this ANOVA model, suggesting most of zolpidem-induced 
sleep was rescued in the HDC-2F77 mice. As we expected, the HDC-2F77 rescue 
mice only differed from 2I77lox mice (n = 4) as a function of zolpidem (mixed-design 
ANOVA, Tukey’s post hoc comparison t (18) = 5.925, p = .002). 
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Figure 3.5. Selective 
potentiation of GABA 
inputs onto 
histaminergic 
neurons allows 
zolpidem to induce 
and maintain sleep: 
EEG analysis.     
a, Sleep latency after 
saline, zolpidem 
(5mg/kg) & pyrilamine 
(5mg/kg) in C57BL/6 (n 
=4; closed black 
circles), 2I77lox (n =4; 
open circles) & HDC-
2F77 mice (n =4; red). 
b, time spent in NREM 
after saline, zolpidem 
(5mg/kg) and 
pyrilamine (5mg/kg) in 
C57BL/6 (closed black 
circles), 2I77lox (open  
circles) and HDC-2F77 
mice (red circles). 
Straight vertical bars 
indicate significance *p 
< 0.05, **p < 0.01, 
Tukey’s post-hoc test; 
n.s., not significant. c, 
Hypnograms after 
zolpidem (5mg/kg; top), 
saline (matched 
volume; middle) and 
pyrilamine (5mg/kg; 
bottom) i.p. injections in 
an HDC-2F77 mouse. 
Traces are aligned 
relative to the time of 
injection (arrow) and 
followed 45 mins after 
injection. NREM (N), 
REM (R) and wake (W) 
are shown as line 
blocks, with the  
ratio, & primary aligned 
EMG & EEG data. The 
 component of the 
EEG is also shown in a 
separate trace. 
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We also analysed the time spent in NREM sleep after drug administration. As, mice 
passively fall asleep in sham saline conditions after approximately 45 (mean) 
minutes (Figure 3.5. a), we analysed the period of time up to 45 minutes after drug 
administration (Figure 3.5. b). Compared with saline, HDC-2F77 mice spent over 
seven fold more time in NREM sleep than after a saline injection (mixed-design 
ANOVA, Tukey’s post hoc comparison t (18) = 6.548, p = 0006). Again, the effect 
was similar to pyrilamine, which increased NREM sleep time six fold (mixed-design 
ANOVA, Tukey’s post hoc comparison t (18) = 5.294 p = .004). Compared with the 
zolpidem insensitive 2I77lox strain, which were confirmed as not statistically different 
between saline and zolpidem, HDC-2F77 mice slept 135% more after zolpidem 
administration (mixed-design ANOVA, Tukey’s post hoc comparison t (18) = 4.383 p 
= .02). Here HDC-2F77 mice did sleep significantly less than C57BL/6 mice with 
zolpidem (mixed-design ANOVA, Tukey’s post hoc comparison t (18) = 4.568 p = 
0.01). Figure 3.5. c shows a representative hypnogram demonstrating the zolpidem-
mediated sleep latency reduction seen in the HDC-2F77 mice (Figure 3.5. c) which 
contrasts with passive, later sleep onset after an injection of saline (Figure 3.5. c) 
(However, see also Appendix 3). As expected, no groups differed as a function of 
pyrilamine on sleep latency or time in NREM. Together the results indicate that HDC 
neurons are important targets of zolpidem both in inducing and maintaining sleep. 
Strengthening inhibition onto histaminergic neurons, and thereby reducing histamine 
tone in the rest of the brain, accounts for a significant part of zolpidem’s sedative 
abilities. This was, although a large effect, not as effective as giving zolpidem to wild-
type C57BL/6 (2F77) mice. We therefore compared zolpidem inhibition of the TMN 
with another putative target area, the frontal cortex (FC). 
 
 
 
97 
 
3.2.4 The frontal cortex is also involved zolpidem mediated sleep. 
 
In some circumstances the frontal cortex could be involved in the initiation of sleep 
(see Introduction). To test if zolpidem might hijack this frontal cortex sleep-promoting 
circuitry as well, we made the frontal cortex of 2I77lox mice selectively zolpidem-
sensitive by genetically swapping zolpidem-sensitive 2F77 subunits into 2I77lox 
frontal cortical neurons, so generating FC-2F77 mice (Figure 3.6. a,b). For voltage 
clamp recordings, we co-injected unilaterally a mixture of two AAVs into the frontal 
cortex, AAV-Cre-2A-2F77 and AAV-flex-rev-EGFP. This produced co-transduced 
neurons. We injected unilaterally so that the other hemisphere could be used for 
negative-control recordings. The swap works as follows. From the AAV-Cre-2A-
2F77 transgene, the Cre recombinase destroys production of functional 2I77, and 
the zolpidem-sensitive 2F77 subunit replaces it; the second AAV expresses EGFP 
only if Cre-recombinase is present, and thus marks neurons which have been 
transduced with AAV-Cre-2A-2F77 (Figure 3.6.a). We visualized the transduced 
area by serial sectioning and immunohistochemistry with GFP antisera (Figure 3.6. 
c,d,e). However, in behavioural experiments, injections of only AAV-Cre-2A-2F77 
were made bilaterally. Anti-Cre immunohistochemistry micrographs were used to 
quantify the spread of AAV in these bilaterally injected brains. In these injections for 
behavioural experiments, the spread of transduced cells reached rostral almost to 
the olfactory bulb and caudal as far as the primary motor cortex (Figure 3.6. d). 
(Note, however, in Figure 3.6. e, EGFP expression from a unilateral injection is 
shown).  AAV-Cre-2A-2F77 transgene expression was found in both the frontal 
motor cortex and the prefrontal cortical areas (including prelimbic cortex, orbital 
areas, primary and secondary motor cortices).  Maximally ~20% of any given cortical 
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area was transduced, mostly in the deep layers of cortex, V and VI (Figure 3.6. e). 
To confirm that the 2I77 to 2F77 swap had produced zolpidem-sensitivity in 
pyramidal neurons of FC-2F77 mice, Dr Zhiwen Ye made acute slices of M1 and 
M2 frontal neocortex and performed whole-cell voltage-clamp recordings on 
pyramidal neurons from layers 5 and 6. The neurons expressing the AAV-Cre-2A-
2F77 transgene were identified by their primary EGFP signal. Zolpidem (1 M) 
slowed the decay of IPSCs by 64% (± 14) in EGFP-expressing neurons (n = 6, t-test, 
p < 0.001) (Figure 3.6. f,g), which was similar to its effect on the IPSCs of C57BL/6 
pyramidal neurons (Figure 3.6. f,g); by contrast, the decay of IPSCs was unchanged 
by zolpidem in 2I77lox neocortical pyramidal neurons (Figure 3.6. f,g). 
 
 
 
99 
 
 
 
 
100 
 
Figure 3.6. (previous page) FC-2F77 mice have frontal cortical neurons 
selectively sensitive to zolpidem. 
a, The AAV-Cre-2A-2F77  and AAV-flex-rev-EGFP  transgenes used to make the 
zolpidem-insensitive 2I77 to zolpidem-sensitive 2F77 subunit swap in 2I77lox mice; 
CAG, cytomegalovirus enhancer/promoter, chicken--actin promoter hybrid; ITR, 
inverted terminal repeats; pA, polyadenylation signal; WPRE, woodchuck 
posttranscriptional regulatory element; b, The two AAVs were mixed and co-injected 
into the frontal cortex of 2I77lox mice; c, Overall expression of the AAV-Cre-2A-
2F77  transgene in pyramidal neurons (e.g. in layer V shown here) was detected by 
EGFP immunocytochemistry;  d, Percentage area of transduced frontal neocortical 
sites along the rostral-caudal axis; e, Wide-field images of EGFP 
immunocytochemical labelling in frontal cortical sections rostro-caudally; note these 
sections are from a unilateral injection of AAV-Cre-2A-2F77  and AAV-flex-rev-
EGFP  into a 2I77lox mouse; f, Peak normalized IPSCs in a cortical pyramidal 
neurons  before (black) and after 1 M zolpidem (red) from C57BL/6 (2F77), 
2I77lox, and an FEC-2F77 neuron;  g, IPSC decay times before and after 1 M 
zolpidem in C57BL/6 (2F77), 2I77lox and FC-2F77 (Layer 6) pyramidal neurons (*p 
< 0.05, paired t-test); n.s., not significant. Dr Zhiwen Ye kindly collected and 
analysed the voltage-clamp data. 
 
To assess if zolpidem promotes sleep by acting on the frontal cortex, we first looked 
at sleep latency and found a significant interaction between mouse type (C57BL/6 vs 
2I77lox) and drug (saline vs zolpidem) (mixed-design ANOVA, F (2,15) = 4.444,  p = 
.03). Compared with saline, zolpidem shortened sleep latency by 57% in FC-2F77 
mice (Figure 3.7. a), this effect showed a trend toward significance (mixed-design 
ANOVA, Tukey’s post hoc comparison t (15) = 2.952, p = .054) (Figure 3f). There 
was a significant between-subjects effect (F (2) = 10.86, p = .001), in which zolpidem 
caused a 67% shorter sleep latency in FC-2F77 mice compared with 2I77lox mice 
(Tukey’s post hoc comparison t (15) = 5.15, p = .006). Next we analysed time spend 
in NREM sleep, again using the cut-off point of 45 minutes after drug administration 
(Figure 3.7 b). Compared with saline, zolpidem increased time in NREM sleep by 
78% in FC-2F77 mice (Figure 3.7. b), also showing a trend toward significance 
(Tukey’s post hoc comparison t (15) = 2.98, p = .052). There was a significant 
increase in NREM sleep time between FC-2F77 mice and 2I77lox mice with 
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zolpidem (Tukey’s post hoc comparison t (15) = 3.865, p  = .04). The increase in 
time in FC-2F77 mice was 48% less than the wild-type zolpidem response seen in 
C57BL/6 mice (Tukey’s post hoc comparison t (15) = 6.055, p = .002). Figure 3.7. c 
shows representative hypnograms demonstrating the zolpidem-mediated sleep 
latency reduction seen in the FC-2F77 mice (Figure 3.7. c) which contrasts with 
passive, later sleep onset after an injection of saline (Figure 3.7. c) (However, see 
also Appendix 3). Taken together, these data suggest that zolpidem can promote 
sleep by acting top-down in the neocortex as well as bottom-up at histaminergic 
neurons. 
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Figure 3.7. The 
frontal cortex 
contributes to 
zolpidem-induced 
NREM sleep: EEG 
analysis.  a, Sleep 
latency after saline 
and zolpidem 
(5mg/kg) in C57BL/6 
(n = 6; black circles), 
2I77lox (n = 6, open 
circles) and FC-
2F77 mice (n =6; 
red circles). b, NREM 
time after saline and 
zolpidem (5mg/kg) 
injections into 
C57BL/6, 2I77lox and 
FC-2F77 mice. 
Straight vertical bars 
indicate significance 
*p < 0.05, **p < 0.01, 
Tukey’s post-hoc 
test; n.s., not 
significant. c, 
Hypnograms after 
zolpidem (5mg/kg; 
top) and saline 
(matched volume; 
bottom) i.p. injections 
in a FC-2F77 
mouse. All traces are 
aligned relative to the 
time of drug or saline 
injection (arrow) and 
followed for the first 
45 mins after 
injection. NREM (N), 
REM (R) and wake (W) are shown as line blocks, together with a segment of the  
ratio below these, and examples of primary aligned EMG and EEG data. The  
component of the EEG is also shown in a separate trace. EEG, 
electroencephalogram; EMG, electromyogram.  
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3.2.5 Control experiments: The superior colliculus is not involved in zolpidem 
mediated sleep 
 
Can zolpidem work in any brain area to induce NREM sleep? To test this we looked 
at the superior colliculi. The superior colliculi are not known to be associated with 
induction or maintenance of NREM sleep, but do regulate eye movements and visual 
attention and also communicate with REM sleep-promoting areas. We made the 
superior colliculi (SC) of 2I77lox mice selectively zolpidem-sensitive.  SC-2F77 mice 
were generated by bilaterally injecting AAV-Cre-2A-2F77 into the superior colliculi of 
2I77lox mice (Figure 3.8. a,b). AAV-Cre-2A-2F77 transgene expression, detected 
by staining with Cre recombinase antisera (Figure 3.8. c), was found throughout the 
layers of the superior colliculi, and maximally transduced about half of the target site 
(Figure 3.8. d). After zolpidem (5 mg/kg) IP injection, the latency to NREM sleep of 
SC-2F77 mice did not differ from that following a saline injection (Figure 3.8. c) 
(ANOVA, F (2, 9) = 2.72,  p = .12, with Tukey’s post-hoc comparison t (9) = .97, p = 
.5), or following zolpidem injection into 2I77lox mice (Figure 3.8. e) (ANOVA, Tukey’s 
post-hoc comparison t (9) = .83, p = .83). The NREM sleep time of SC-2F77 mice 
was also not increased: during the first 45 minutes after zolpidem administration 
(Figure 3.8. f), SC-2F77 mice slept as little as the zolpidem-injected, but zolpidem-
insensitive 2I77lox mice, and both groups slept significantly less than zolpidem-
injected C57BL/6 mice (mixed-design ANOVA F (2,9) = 8.62, p = 0.008 with Tukey’s 
post-hoc comparison t (9) = 8, p = .0008) (Figure 3.8. f). Zolpidem did not change the 
proportion of REM sleep in SC-2F77 mice in the first 45 mins after injection (not 
shown). 
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Figure 3.8. The superior colliculi do not contribute to zolpidem-induced sleep.    
a, Generating SC-2F77 mice: the AAV-Cre-2A-2F77  transgene used to make the 
zolpidem-insensitive 2I77 to zolpidem-sensitive 2F77 subunit swap in 2I77lox mice; 
CTX, neocortex; CAG, cytomegalovirus enhancer/promoter, chicken--actin 
promoter hybrib; ITR, inverted terminal repeats; pA, polyadenylation signal; SC, 
superior colliculi; WPRE, woodchuck-posttranscriptional-regulatory-element; b, 
Bilateral AAV-Cre-2A-2F77 microinjection into the superior colliculi of  2I77lox 
mouse brain to generate SC-2F77 mice; c, detection of  AAV-Cre-2A-2F77  
transgene expression in the SC by anti-Cre immunohistochemistry; d, Percentage 
area of AAV-transduced SC along the rostro-caudal axis; e, Sleep latency after 
saline and zolpidem (5mg/kg) injections in C57BL/6 (n = 4; grey circles), 2I77lox (n = 
4; grey circles) and SC “2-swap” mice (n = 4; red); f, NREM time after saline and 
zolpidem (5mg/kg) in C57BL/6, 2I77lox and SC-2F77 mice. Straight vertical bars 
indicate significance **p < 0.01, ***p < 0.001 Tukey’s post-hoc test; n.s., not 
significant. 
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3.3 Discussion 
 
We have demonstrated that enhancing synaptic GABAergic inhibition at HDC-
neurons is sufficient to induce sleep. This is consistent with the Flip-flop model of 
sleep-wake control (Saper et al., 2005). Interestingly, removing GABAergic inhibition 
chronically, in these neurons, does not produce an obvious phenotype, regarding 
normal sleep-wake regulation (Zecharia et al., 2012). However an acutely acting 
pharmacogenetic approach, which is not susceptible to genetic compensation, 
reveals that those cells are involved in sleep induction after all. The outcome here is 
analogous to the results by Wulff et al. (2007), in which pharmacologic modulation of 
PCs produced a pronounced behavioural effect despite chronic PC-2 mice 
displaying a normal motor phenotype. They found the cerebellum was a substrate of 
zolpidem-mediated ataxia. Accordingly, we find HDC-neurons are a substrate of 
zolpidem-mediated sleep. 
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Another arousal nucleus that would have been interesting to look at may have been 
the orexinergic LHA. The LHA would have also been relevant to this project, bearing 
in mind evidence of its role in sleep caused by GABAA receptor PAMs (Panhelainen 
and Korpi, 2012). Considering the LHA projects directly onto the TMN to excite 
histaminergic neurons (Bayer et al., 2001, Eriksson et al., 2001, Peyron et al., 1998), 
it may be that the HDC neurons were not fully silenced by zolpidem in these in vivo 
experiments. Perhaps this accounts, in part, for the small discrepancy between 
HDC-2F77 mice and the wild-type mice. It may have been interesting to perform a 
2F77-rescue experiment in the LHA. We could have achieved this using the same 
experimental setup as the HDC-neuron experiments. By crossing Orexin-Cre mice 
(Matsuki et al., 2009) with 2I77lox mice, we would have generated Orexin-2 mice. 
Then, by injecting AAV-flex-rev-2F77-2A-Venus into the LHA, we would have 
created mice with zolpidem sensitivity selectively in the LHA. It seems reasonable to 
assume this would promote sleep, as seen previously using the inhibitory DREADD 
receptor hM4D (Sasaki et al., 2011). It may have been interesting to follow this by 
generating mice with sensitivity in both histaminergic neurons and orexinergic 
neurons. Synergistic effects on wake promotion has been reported previously 
regarding these two brain nuclei (Anaclet et al., 2009). Perhaps zolpidem might then 
shorten sleep latency to the same degree as in wild-type mice. The reason we did 
not pursue this, however, was due to the fact that Cre does not seem to express in 
the majority of orexin neurons but rather approximately half of them (Matsuki et al., 
2009). We were concerned that these experiments might not invoke zolpidem-
sedation to the same degree as in wild-type animals. In which case, would the result 
mean histamine and orexin neurons together cannot elicit full zolpidem-sedation; or 
rather we had just failed to target all of the relevant cells? 
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Interestingly, the frontal cortex is also involved in zolpidem-induced sleep. Although 
the frontal cortex is involved in higher order cognitive function, this influences the 
onset of sleep (Steenland, 2014). Further, specific cortical activity represents stages 
of sleep and waking and local cortical sleep spreading throughout the cortex has 
been seen before (Vyazovskiy et al., 2011, Massimini et al., 2004) and leads to 
behavioural sleep (Peñaloza-Rojas et al., 1964). Further, these oscillations have a 
tendency to originate in frontal regions specifically the insular and cingulate cortices 
(Murphy et al., 2009). We postulate that local effects of zolpidem in the frontal cortex 
synchronize wider sleep circuitry i.e. the cortico-thalamic loop. Perhaps excitatory 
input to the thalamus by the cortex becomes inhibited; enabling thalamic neurons to 
return to a default synchronized oscillatory state (see introduction), in turn, leading to 
synchronized -oscillations globally. This pharmacologic LOC mechanism has been 
discussed previously in the context of general anaesthesia (Franks, 2008) and the 
results here support that notion in sedative-hypnotic drugs. Other parts of the brain 
do not affect this positive-feedback circuitry and are dispensable in zolpidem-sleep 
induction, as seen in SC-2F77 mice. 
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Following this line of thought, we had wanted to investigate the paraventricular 
thalamic nucleus (PVT). The PVT has high endogenous 2-subunit containing 
GABAA receptor expression, as well as 1 and 3 subunit containing receptors 
(Hörtnagl et al., 2013, Wisden et al., 1992), which means that zolpidem will act upon 
this nucleus. As mentioned in the general introduction, GABAA receptors with 1 
subunits are important for zolpidem motor sedation. Also, 12F77 and 32F77 
receptors (as well as 22F77) are required for zolpidem sensitivity (Ramerstorfer 
et al., 2010).  And the PVT plays a broad role in behaviour, including sleep-wake 
regulation (Martin-Fardon and Boutrel, 2012), receiving inputs from the wake active 
orexinergic LHA (Kirouac et al., 2005) that release orexins to depolarize the PVT 
neurons (Ishibashi et al., 2005). PVT cells fire at different rates during the light phase 
and the dark phase (Kolaj et al., 2012, Kolaj et al., 2007). Together, the evidence 
points to a role for the PVT in sleep-wake regulation. However, whether there is a 
relationship between zolpidem, the PVT and sleep-wake control remains an open 
question. I had planned to use the virus-mediated “2-swap” method to investigate its 
potential role in zolpidem mediated sleep. But because of technical set-backs there 
was not a conclusive result. Because the PVT is situated just below the third 
ventricle, stereotaxic injections were very difficult. Most of the injections were failures 
(6 out of 7) probably because the virus gets flushed from the site by CSF in the third 
ventricle. The other problem was that even when the PVT had been targeted, there 
was diffuse viral-transduction throughout the brain, most likely also due to the active 
movement of CSF near the injection site. We had considered solving the issue of off 
target expression by using a Cre-mouse line in which Cre is expressed under the 
control of the glutamate receptor metabotropic 2 (Grm2) promoter, and expresses 
Cre in the PVT (Gensat, 2015). To this end we had considered crossing the Grm2-
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Cre strain with 2I77lox strain and using the Cre-dependent AAV construct we used in 
the HDC neuron experiments. This would have improved off target expression. 
However, Cre is not restricted to the PVT in the Grm2-Cre line. Cre is found in other 
thalamic nuclei as well as many other areas including the cortex, hippocampus and 
hypothalamus. So this would have resulted in a wide-spread 2 knockout strain with 
2-rescue in the PVT. We felt neither of the approaches at our disposal was suitably 
specific and so we did not pursue this line of research any further. 
 
The results of this chapter underpin the mechanisms of hypnotic drugs at the 
systems level; BZs and other Z-drugs, which share the same molecular targets, 
presumably employ similar mechanisms to induce sleep (However, see General 
Discussion). Understanding that parts of the brain are non-essential in drug-induced 
sleep supports the development of new drugs which might act more selectively upon 
sleep-wake regulating brain circuitry, an example may be DORAs (Scammell and 
Winrow, 2011). 
 
3.3.1 Conclusions 
 
Zolpidem has rather subtle effects on synaptic IPSCs. Typically, it prolongs them by 
around 50%. Our null hypothesis was that it induced sleep by potentiating IPSCs 
everywhere in the brain, and as these small prolongations of IPSCs summed up, the 
net effect, by slowing the entire network down, would be behavioural sleep. But 
instead we have shown that zolpidem can induce sleep quite effectively by 
augmenting GABA input in discreet brain regions (frontal cortex) or even just on one 
cell type (histamine neurons). For neither the frontal cortex nor the histaminergic 
neurons was the full sleep time obtained compared with giving zolpidem to wild-type 
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mice; in both cases it was about half the time of zolpidem on C57BL/6 mice. One 
explanation is that we did not transduce all the neurons in these areas. A second 
explanation is that there will certainly be other additional areas that zolpidem could 
also work on, and these will summate. The particular pharmacogenetic method we 
used is based on up regulating an endogenous GABA input. So, because it is 
modulating natural inhibitory pathways, the “zolpidem method” could reveal if GABA 
inputs in other circuitries have the potential to induce sleep. 
 
  
 
 
111 
 
4. Fast synaptic GABA inhibition onto cortico-thalamic 
pyramidal neurons in isoflurane anaesthesia and sleep-
wake regulation 
 
4.1 Chapter Introduction 
 
As discussed in the general introduction, cortico-thalamic (CT) neurons and 
functional connectivity between the cortex and the thalamus are believed to be 
important for the generation of -oscillations and the transition from waking into 
NREM sleep. Sleep can be induced by modulating activity locally at the neocortex 
(Peñaloza-Rojas et al., 1964). And the inhibition of excitatory drive onto the thalamus 
by the cortex is thought to be a possible common mechanism between anaesthesia 
and natural sleep-wake regulation (Franks, 2008). If this were the case, perturbing 
this system should have some profound effects on wakefulness, considering that 
consciousness may be, in essence, the integration of modular sensory information 
(Alkire et al., 2008). However the “nature of consciousness” can be an elusive 
concept. So perhaps the fact that cortico-thalamic functional connectivity is a key 
focal point in the systems neuroscience of sleep and anaesthesia (Franks, 2008) is 
an even more compelling rationale to pursue this line of investigation. 
 
We therefore decided to investigate the role of fast synaptic inhibition onto CT-
neurons which constitute a principle neocortical output, and how this affects 
physiologic sleep-wake control, activity levels in waking and anaesthetic drug 
induced LOC. We deleted the GABAA-2 subunit gene selectively in layer-6 CT- 
neurons to lesion fast synaptic GABAergic inhibition onto those cells. A distinct sub-
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population of pyramidal neurons in layer-6 of the neocortex expresses Cre-
recombinase in the Ntsr1-Cre transgenic mouse line (Bortone et al., 2014). These 
cells constitute approximately 60% of all the neurons in layer-6 but are exclusive to 
this layer in the neocortex. They are involved in gain control in the other layers of the 
cortex. Generally, when more active, these neurons dampen the activity in the other 
layers by di-synaptic inhibition via layer-6 fast-spiking GABAergic interneurons. 
Crucially for our work, Ntsr1-Cre neurons are exclusively cortico-thalamic projecting 
neurons and constitute a major source of communication from the cortex to the 
thalamus, the other major source is cortico-thalamic neurons of layer 5 (Harris and 
Mrsic-Flogel, 2013). Interestingly, layer 6 neurons can have - the opposite effect - an 
excitatory influence on layer 5a. The layer 6 CT-neurons in the visual system project 
to primary-visual thalamus (lateral geniculate nucleus; LGN)(Bortone et al., 2014). 
Also, the layer 6 CT-neurons of the somatosensory cortex project to the primary 
sensory thalamus (ventro-posteriomedial nucleus) (Mease et al., 2014, Landisman 
and Connors, 2007) and the layer 6 CT-neurons of the auditory cortex project to the 
primary auditory thalamus (ventral part of the medial geniculate body)(Lee et al., 
2012). The functional connectivity of the layer 6 CT-neurons is less clear for other 
sensory modalities. However in the primary motor system, layer 6 CT-neurons have 
virtually no functional connectivity with the motor thalamus (Ventrolateral nucleus; 
VL) (Yamawaki and Shepherd, 2015). So there is possibly a dichotomy; that Ntsr-
Cre neurons are CT-neurons in sensory systems, but not in motor systems. This is 
highlighted by the expression pattern of Cre in the Ntsr1-Cre line (Gensat) which 
shows stronger Cre expression levels in posterior cortical areas which contain 
sensory nuclei. Whereas anterior areas containing motor nuclei, and higher order 
executive functioning areas, show lower Cre levels. It also seems that layer 6 CT-
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neurons are principally involved in primary sensory cortico-thalamic communication 
in general, whereas layer-5 CT-neurons are involved in higher order or “non-specific” 
cortico-thalamic communication (Sherman, 2012). Layer-5 Cre lines, on the other 
hand do not selectively mark CT-neurons (Gensat). 
 
We generated a novel mouse line termed L6-2 by crossing Ntsr1-Cre mice with 
GABAA-2I77
lox mice to delete synaptic GABAA receptors from layer-6 pyramidal 
neurons. We looked at normal sleep wake patterns as assessed by EEG and EMG 
as well as EEG -oscillation in NREM and waking. We also looked at motor activity 
during waking. We also analysed dose responses of isoflurane upon LORR as well 
as time to LORR, RRR and brief emergence. 
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4.2 Results 
 
4.2.1 Lesioning fast synaptic inhibition in layer-6 CT-neurons 
 
To visualize target neurons we stereotaxically injected AAV-flex-EGFP into deep 
neocortical tissue of L6-2 mice to selectively mark Cre-positive neurons (Figure 
4.1. a). For this we chose to inject in primary visual cortex because we were 
confident that Cre was expressed well in this region (Bortone et al., 2014). We found 
that the EGFP expression in cell bodies was restricted to layer-6 cortical tissue 
(Figure 4.1. b). However, EGFP expression in axon terminals can also be seen in the 
primary visual area of the thalamus, the LGN (Figure 4.1. b). This confirmed that the 
Cre-positive neurons were indeed CT-neurons and it facilitated whole-cell voltage 
clamp recordings in the Ntsr-Cre neurons, as assessed by biocytin/EGFP co-
localization (Figure 4.1. c). Next, we wanted to confirm that we had lesioned 2-
subunit expression in these neurons. We double stained with the neuronal marker 
NeuN (Figure 4.1. d, green) and anti-2 antisera (Figure 4.1. d, red) and found that 
GABAA-2 subunits were removed from sub-sets of neurons in layer 6 of the L6-2 
mice (figure 4.1. d, top) but not the Cre-negative littermate controls (figure d, 
bottom). 
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Figure 4.1. (previous page) Selective deletion of GABAA-2 subunits in layer-6 
CT-neurons.       a Ntsr-Cre mice were crossed with GABAA-2I77
lox mice to 
generate L6-2 mice and AAV-flex-EGFP was injected into layer-6 of primary visual 
cortex of L6-2 mice to visualize Cre-positive neurons. b Cre-positive neurons, 
which are expected to have 2-subunit ablation, express Cre-dependent EGFP and 
their axon terminals can be seen in the lateral geniculate nucleus (LGN) of the 
thalamus, where visual neocortical CT-neurons project. c top Cre-positive cell 
bodies of layer 6 tissue, marked with EGFP, bottom a biocytin filled neuron (red) 
which is Cre positive, as determined by Cre-dependent EGFP expression (green) co-
localization (yellow). d NeuN and 2 antisera co-staining reveals that 2-subunits 
were removed from this sub-population of neurons. Top Low magnitude image of a 
coronal section of brain taken from an L6-2 mouse, the white square indicates the 
blown up portion. NeuN staining marks neurons (green), anti-2 staining (red) shows 
neurons with intact 2-subunit expression, a merged image (yellow) reveals co-
localization and the arrows indicate neurons from which 2-subunits have been 
ablated. Bottom the same treatments performed on a Cre-negative littermate 
reveals 2-subunits remain present. Dr Zhiwen Ye kindly performed the biocytin fill 
for panel c, bottom. 
 
4.2.2 L6-2 virtually abolishes IPSCs in CT-neurons 
 
To verify that GABAA-2 knock-out in layer-6 CT-neurons had removed IPSCs in the 
cell population, Dr. Zhiwen Ye performed voltage-clamp recordings on Cre-positive 
Ntsr-1 neurons marked by Cre-dependent GFP expression. The neurons were then 
biocytin-filled to visualize the morphology of the cells (Figure 4.2. a). We found that 
IPSCs were virtually abolished in the EGFP-marked neurons (Figure 4.2. b, red 
trace) compared with Cre-negative littermates (Figure 4.2. b, black trace). It was 
apparent that a small number of inhibitory currents remained in the L6-2 pyramidal 
neurons, however the frequency of these events was reduced by 94% (Figure 4.2. 
c)(two-tailed unpaired t-test, t (9) = 5.83, p = .0001). Furthermore, these residual 
currents had abnormal kinetics (Figure 4.2. d). The weighted decay was nine fold 
slower than in normal IPSCs (two-tailed unpaired t-test, t (9) = -14.43, p = 7.9 ×
10−8). 
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Figure 4.2. Whole-cell voltage-clamp recordings in L6-2 and Cre-negative 
littermate control pyramidal neurons. a Biocytin filled pyramidal neurons used in 
voltage-clamp recordings expressing EGFP mediated by AAV-flex-EGFP which 
marks Cre expression in the cell. b Example traces of voltage clamp recordings 
showing normal IPSCs have been removed from the L6-2 neurons (red), whereas 
IPSCs in wild-type layer 6 pyramidal cells are intact (black). c Frequency of IPSCs in 
layer-6 pyramidal neurons in Cre-negative littermate control mice (n = 6; black) and 
L6-2 pyramidal cells (n = 5; red). d representative traces of IPSCs from a wild-type 
layer-6 pyramidal neuron (black) and slower mIPSCs from  a L6-2 pyramidal cell 
(red). *** indicates p<.001. Dr Zhiwen Ye, kindly provided the data used in this figure. 
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4.2.3 Lesioning fast synaptic inhibition of layer-6 CT-neurons does not perturb 
the transition from waking to NREM sleep but it alters the quality of NREM 
sleep 
 
Next, we looked at normal sleep-wake regulation. We recorded EEG and EMG over 
24 hours in L6-2 mice (n = 6) and littermates (n = 6). Surprisingly, normal sleep-
wake patterns were conserved (Figure 4.3. a) with relatively more waking during the 
dark phase and more NREM and REM sleep in the light phase. Figure 4.3. b shows 
hypnograms of a L6-2 mouse (top) and littermate control (bottom), these illustrate 
the presence of normal transitions from wake into NREM and REM sleep. However, 
the EEG power spectrum profile reveals differences between the strains. L6-2 
mice (n = 6) have significantly less NREM sleep -power than Cre-negative 
littermates (n = 5), (two-sample t-test t (14) = -3.81, p = .002) indicating that although 
NREM sleep is conserved in these mice, their quality of NREM sleep has been 
altered. By contrast, -oscillation power in waking were not significantly altered (two-
sample t-test t (14) = .772, p = .453) between the L6-2 mice and the Cre-negative 
littermates. 
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Figure 4.3. (previous page) Sleep-wake patterns and transitions in L6-2. a, 
Percentage wake (top), NREM sleep (middle), and REM sleep (bottom) of L6-2 
mice (red), and Cre-negative littermates (black). The grey area indicates the dark 
phase and the white area indicates the light phase. b, Representative hypnograms of 
L6-2 (top) and Cre-negative littermates (bottom) with accompanying traces of 
ratio, EEG, EMG and root-mean-squared -oscillations. c, EEG power spectra of 
10 minute periods during NREM sleep (top) and waking (bottom). -oscillations (~1 
Hz ~4 Hz) are represented by the horizontal black lines above the x-axis, ** indicates 
p < 0.01, un-paired t-test, n.s. indicates not significant. 
 
 
4.2.4 L6-2 mice are hyperactive in a novel open field environment 
 
Removing GABAergic inhibition onto layer-6 CT-neurons should disinhibit 
glutamatergic drive onto primary thalamic nuclei. We wanted to see if this would 
produce behavioural level effects. We placed L6-2 mice and littermates in a novel 
open field environment which recorded x,y coordinates by infrared beam breaks 
(activity monitor). Figure 4.4. b & c are representative heat-maps of a L6-2 mouse 
and a Cre-negative littermate respectively, showing the number of visits to a 
coordinate over a fixed period of ten minutes. During this time, L6-2 mice (n=5) 
travelled further than littermates (Figure 4.4. d; n=5). They also initiated more bouts 
of movement during that time (Figure 4.4. e). L6-2 and Cre-negative littermate 
control mice were subjected to trials in a systematic cross-over design to remove 
habituation related confounds. We considered that because we had disturbed 
GABAergic signalling, these motor effects could be secondary to an anxiety 
phenotype. So, we analysed thigmotaxic behaviour, a proxy of anxiety in mice. L6-
2 mice were normal here (Figure 4.4. f), suggesting that they have a general 
hyperactive phenotype not related to anxiety. 
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Figure 4.4. Open field activity levels of L6-2 mice. a, Activity levels in awake 
mice were assayed by infrared beam crosses in an open field environment, 
coordinates of which can be divided into centre (white) and edge (grey) zones to 
provide a measure of thigmotaxis. b, representative heat map of an L6-2 mouse. 
c, representative heat map of a Cre-negative littermate control mouse. Hotter colours 
indicate more visits to a specific coordinate, while cooler colours indicate fewer visits 
to a particular coordinate. Heat maps are useful because the resolution provided by 
the infrared beams is only 16 by 16. Thus, more information is gained by looking at 
repeat visits to the same place. d, Box plot of distance travelled (meters) in the open 
field during ten minutes. e, Box plots of ambulatory bouts, which is episodes of 
movement across the open field. f, box plots of time spent in the centre vs the edge 
of the open field, i.e. thigmotaxis. Upper bars = max, box tops = +SEM, mid line = 
median, box bottom = -SEM, lower bar = min. * indicates p < 0.05. Elly Steinberg 
kindly performed Matlab coding required for generating the heat-maps of panels b & 
c. 
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4.2.5 Fast synaptic inhibition of layer-6 CT-neurons is involved in isoflurane 
anaesthesia 
 
During surgeries to implant EEG and EMG electrodes, the L6-2 mice were 
apparently less responsive to isoflurane. They seemed to take longer to become 
anesthetized. So, I decided to test this systematically. We used LORR as a proxy of 
LOC. First we tested the concentration of isoflurane that induced LORR. By exposing 
L6-2 mice and Cre-negative littermates - with intact fast synaptic inhibition in layer-
6 CT-neurons - to increasing incremental concentrations of isoflurane, we found the 
ED50 was shifted to the right in the L6-2 mice, i.e. the L6-2 mice were less 
sensitive to isoflurane (Figure 4.5. a). This indicated that fast-synaptic inhibition onto 
the glutamatergic excitatory layer-6 CT-neurons is an important mechanism in 
isoflurane anaesthesia. 
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Next, we looked at latency to LORR (Figure 4.5. b) and RRR (Figure 4.5. c). We 
found that, on average, L6-2 mice took significantly longer to become 
anaesthetized by isoflurane than Cre-negative littermates (n=10, two-sample t-test t 
(18) = 2.9739, p = .008). This also illustrated a diminished sensitivity to the drug. 
Interestingly however, latency to RRR was not different between the two strains 
(n=10, two-sample t-test t (17) = -.372, p = .715), suggesting that the circuitry we had 
perturbed might be specifically involved in anaesthetic induction rather than 
emergence from isoflurane anaesthesia. During the 10 minute anaesthesia 
maintenance period, some mice transiently regained muscle tone to attempt to right 
themselves, consistent with previously described criteria (Devor and Zalkind, 2001). 
These events, termed here as brief emergences (Figure 4.5. d), occurred 
significantly more in the L6-2 mice, (two-sample t-test t (16) = 2.33, p = .034) 
suggesting that inhibition by GABAA-2 receptors on the layer-6 CT-neurons is also 
an important mechanism in the maintenance of isoflurane anaesthesia in vivo. 
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Figure 4.5. Isoflurane sensitivity of L6-2 mice. a Waud’s dose response curve 
with individual animals, awake vs anaesthetised, plotted by the curve: L6-2 mice 
(open circles) and Cre-negative controls (closed circles). Squares = ED50. b box 
plots of time (minutes) to LORR, L6-2 mice (left; n=10), Cre-negative mice (right; 
n=10). c box plot of time (minutes) to RRR, L6-2 mice (left; n=10), Cre-negative 
mice (right; n=10). High bar = max, box top = +SEM, mid-line = median (b) or mean 
(c), box bottom = -SEM, low bar = min. d Brief emergence from anaesthesia. Circles 
= raw data. Squares = mean, error bars = SEM. * indicates p < 0.05, ** indicates p < 
0.01, n.s. indicates not significant. 
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4.3 Discussion 
 
The results of this study demonstrate that fast synaptic-GABAergic inhibition onto 
layer-6 CT-neurons is an important substrate of isoflurane anaesthesia. It seems one 
mechanism of isoflurane anaesthesia is to promote this type of inhibition in the CT 
pathway. So, by removing this mechanism, isoflurane sensitivity in the animal in vivo 
was reduced. This is in line with the hypothesis that general anaesthetics cause LOC 
via the neocortex. Other mechanisms involving NMDA receptors and TASK and 
TREK channels were left intact, as well as extra-synaptic GABAA receptors in layer-6 
neurons, and all GABAA receptors in the rest of the brain. But by removing this one 
target, more isoflurane was needed to induce anaesthesia. In principle, isoflurane 
binding to GABAA receptors was not altered in this study. Isoflurane binds at the 
interface between  and  subunits. Therefore the binding pocket has been left 
intact. However, by removing the 2-subunit, phasic inhibition is perturbed. Tonic 
inhibition is also modulated by isoflurane (Jia et al., 2008), so it is interesting to see 
the involvement of phasic inhibition. Furthermore, by removing the 2-subunit, the 3-
subunit may have replaced some of the effect of the deletion (Kerti-Szigeti et al., 
2014). This is consistent with finding slow inhibitory currents in the L6-2 neurons, 
which is similar to another 2 deletion study in which 2-subunits were deleted from 
parts of the neocortex using virus-mediated Cre in the same 2I77lox mouse strain 
used in this study (Kerti-Szigeti et al., 2014). Zecharia et al. (2012) made HDC-2 
knock-out mice, but never reported any mIPSCs of this nature; similarly 2-subunit 
deletion in PCs removed IPSCs (Wulff et al., 2007, Wulff and Wisden, 2005). 
Perhaps 2 knock-out in the neocortex is more severe for the animal, and genetic 
conservation of fast-synaptic inhibition is particularly active in this area. It is apparent 
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that the slower kinetics and negligible residual frequency of inhibitory currents in L6-
2 neurons cannot sustain normal isoflurane sensitivity in the animal in vivo. 
Isoflurane anaesthesia must rely, to some extent, on modulating the specific timing 
of inhibitory events in the cells. 
 
The hyperactive novel environment phenotype is surprising considering that the 
layer-6 CT-neurons marked by Ntsr1-Cre are primarily involved in sensory systems 
rather than motor systems. That being said, because the L6-2 mice seem normal 
in their home cages, the hyperactivity seems to be specific to novelty. It would make 
sense that this observable behavioural effect is secondary to a non-observable 
sensory effect. 
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Figure 4.6. Lesioning fast-phasing inhibition in layer 6 CT-neurons removes a 
mechanism of isoflurane anaesthesia. Left. When GABAA receptors containing 2 
subunits are intact, normal synaptic localization confers regular fast phasic inhibition. 
Normal levels of isoflurane potentiates this and excitation from the cortex to primary 
thalamic areas becomes dampened. TC-neurons enter burst firing. Right. When 2-
subunits are removed, there are either no GABAA receptors in the synapse, or 
possibly very low levels but with 3-subunits which cannot produce the required 
frequency or kinetics of IPSCs. Isoflurane is left only with other mechanisms to 
induce LOC, and thus more of the drug is required to produce the effect. 
 
 
4.3.1 Cortico-thalamic networks in anaesthesia 
 
The original idea that the thalamus is an anaesthetic switch was drawn from imaging 
studies which revealed a deactivation of the thalamus during general anaesthesia. 
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However, poor temporal resolution provided by imaging studies left the causal role of 
the thalamus unclear (Mashour and Alkire, 2013). Two schools of thought remain. 
One is that initial changes during anaesthesia originate in the thalamus; the other is 
that the thalamus provides a mere read-out of the changes that occur in the cortex. A 
recent study in humans compared the temporal changes in the cortex (measured by 
EEG) versus the thalamus (measured by subcortical ESCoG). The authors 
concluded that sevoflurane and propofol anaesthesia involve top-down processes 
(Velly et al., 2007). The conclusion stated that LOC lead to increased -power and 
decreased -power in the cortex first. This change occurred in the thalamus too, but 
later. Unfortunately, time-scales were measured by stages during surgery 
(immediately after LOC, before intubation, after intubation etc.). So the temporal 
detail is vague. Also, a problem with this conclusion is that it is based on a shift from 
faster () to slower ( median power frequencies at the first arbitrary time point in 
the cortex, which is significantly larger than a small shift in the same direction in the 
thalamus. That does not mean the shift definitively took place in the cortex first; but 
rather the effect was larger in the cortex earlier. This issue is highlighted by the 
percentages of -power and -power in the two brain areas during propofol 
anaesthesia. The changes are actually very similar, only the magnitude is greater in 
the cortex. Ideally, the study would have included time points frequent enough to 
show an “anaesthetic-on” period, in which the effect is present in the cortex and 
absent in the thalamus. However, this would presumably be too impractical which 
may be the reason for the temporal resolution the authors reported. However a 
recent study in rats, conducted in our lab, demonstrated that at very short 
timescales, (fractions of a second) which cannot be recorded with current imaging 
techniques (typically >10 seconds), these oscillatory changes occur in the thalamus 
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before they occur in the cortex, leading up to LORR during propofol anaesthesia 
(Baker et al., 2014). Unfortunately, comparing injectable agents with volatile agents 
may be rather tenuous, and the simplicity of the current knock-out study lacks the 
temporal precision to provide information about the anatomical origin of anaesthesia. 
Nevertheless, the studies described above also contribute to our growing 
understanding that anaesthetics are not non-specific, and they work by influencing 
particular networks in the brain. In line with that, it is interesting that GABA signalling 
in the descending part of the cortico-thalamic loop is involved in isoflurane 
anaesthetic induction and maintenance. 
 
Another possible explanation, however, is that the important element lies in the 
cortex alone. There is a great deal of functional cortico-cortical connectivity between 
the layer-6 CT-neurons and the other layers of the cortex (Bortone et al., 2014, 
Harris and Mrsic-Flogel, 2013, Harris and Shepherd, 2015). Timing between 
connected areas conveys distinct information (Crandall et al., 2015), and GABAergic 
transmission is critical in timing/synchrony between different areas (Rudolph and 
Möhler, 2013, Klausberger and Somogyi, 2008, Gupta et al., 2000, Möhler, 2006). 
Perhaps isoflurane interferes with GABA signalling here, and perturbs finely tuned 
timing between different parts of the cortex to interrupt information integration and 
cause LOC (Alkire et al., 2008, Massimini et al., 2007). Thus, by removing fast-
synaptic inhibition on CT-neurons we have essentially removed this mechanism that 
isoflurane influences. 
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4.3.2 Future directions 
 
It would be useful to follow up this work by confirming that 3-subunits are 
responsible for these slow mIPSCs. Similar to Kerti-Szigeti et al. (2014), we could 
use DMCM, a -carboline, which acts as an inverse agonist at 2 and 3-subunit 
containing GABAA receptors but potentiates 1-subunit containing GABAA receptors. 
Serendipitously, these experiments were carried out on the 2 floxed mice which 
bear the 2-I77 point mutation. The point mutation is not involved in isoflurane 
binding or normal GABAergic transmission, but it abolishes DMCM sensitivity (Ogris 
et al., 2004). So any residual 2-subunit containing GABAA receptors would be 
insensitive to DMCM. Therefore we could clearly discern between the three types of 
-subunit. It would also be important to work out the other GABAA receptor sub-units 
left after the lesion.  For example, five -subunits are found in the cortex (1-5) 
(Hörtnagl et al., 2013, Wisden et al., 1992). Would their relative proportions remain 
after the 2-subunits have been removed? 
 
The results here also support the notion discussed in Chapter 3, in which excitatory 
drive onto thalamic neurons becomes inhibited enough to facilitate a transition into 
burst-firing by thalamic neurons. Whether this is indeed a parallel between 
physiologic sleep and anaesthesia is not quite addressed by this work though, 
because there were no effects on the normal sleep-wake cycle, except that NREM 
sleep -power was lower. We suspect that this muted result is not evidence that the 
descending pathway of the cortico-thalamic loop is less important in sleep-wake than 
previously thought. But rather, the effect of knocking out 2-subunits in the layer-6 
CT-neurons was masked by genetic compensation. As this was a chronic knock-out 
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study, genetic compensation could be expected. It would be reasonable to 
hypothesise that something adaptive and vital, such as sleep-wake regulation, is 
conserved during development. However by introducing a short-acting reversible 
agent – isoflurane – we have provided a factor that genetic compensation is not 
equipped to counter. Thus effects are revealed. This is in line with results from 
chronic deletion of GABAA-2 subunits in cell populations in which subtle or no 
behavioural effects were observed (Wulff et al., 2007, Zecharia et al., 2012). A more 
powerful tool would have been pharmacogenetic modulation of the population of 
cells as seen in both Wulff et al. (2007) and in Chapter 3 of this thesis. We 
considered using this approach. However, virus-mediated 2-swap by stereotaxic 
injection would not have been realistic for targeting such a broad region of the brain. 
A more precise approach would have been to follow the paradigm described in Wulff 
et al. (2007) to create a mouse line which expressed GABAA-2F77 receptors under 
the control of the Ntsr1 promoter and cross the mice with the L6-2 mice. We could 
then acutely modulate the CT-neurons with zolpidem and DMCM. However due to 
the time restrains of this project we did not follow this line of work. It could be an 
interesting future pursuit. 
 
In summary, chronically removing GABAA-2 subunits from layer-6 CT-neurons 
produces subtle effects on sleep-wake, which may be due to genetic compensation. 
But, by testing isoflurane sensitivity, which the mice are less or not equipped to 
compensate for, we see obvious effects of removing this specific type of neuronal 
inhibition. And this demonstrates that layer-6 CT-neurons are important substrates of 
arousal and key targets in isoflurane anaesthesia. 
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5. General Discussion 
 
In this thesis I have explored how GABAA receptor PAMs interact with sleep-wake 
circuitry in the brain. Specifically, I looked at a common “sleeping pill”, zolpidem, and 
an inhalable anaesthetic, isoflurane. 
  
By introducing zolpidem-sensitivity specifically in histaminergic HDC-neurons of the 
hypothalamus, as well as the frontal cortex in zolpidem-insensitive mice, we showed 
that both target sites not only conferred zolpidem-enhanced IPSCs, but shortened 
sleep latency in vivo. The results show that zolpidem can induce sleep by both 
bottom-up and top-down mechanisms. 
 
Secondly, I found a role for fast-synaptic GABAergic inhibition onto CT-pyramidal 
neurons in general anaesthetic induction and maintenance. By deleting GABAA-2 
subunits in layer-6 CT-pyramidal neurons of Ntsr1-Cre mice crossed with GABAA-
2I77lox mice (L6-2), we found a higher concentration of isoflurane was needed to 
induce LORR. Also, more time was needed to induce LORR in the L6-2 mice, than 
their Cre-negative littermates. Brief emergences from anaesthesia were also more 
common in the knock-out mice. However, time until RRR was the same in both 
groups. L6-2 mice were also hyperactive in a novel environment. But normal sleep 
wake patterns – assessed by EEG and EMG – were essentially normal, except for 
NREM sleep -oscillation power which was significantly reduced. 
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5.1 Other sedative-hypnotics drugs 
 
The systems level mechanisms that we have begun to understand here about 
zolpidem can be related closely to other similar drugs. For example the other popular 
z-drug zopiclone has almost the same pharmacologic mechanisms as zolpidem. And 
eszopiclone is simply the S-enantiomer of zolpiclone (Monti and Pandi-Perumal, 
2007). Zopiclone binding is also abolished in the GABAA-2-I77 point mutant receptor 
(Ramerstorfer et al., 2010). Further, zopiclone potentiates GABAA receptors to 
essentially the same degree via the same isoforms of the receptor i.e. 1-3,,2; the 
exception is zopiclone potentiates 5,,2-GABAA receptors as well whereas 
zolpidem does not (Ramerstorfer et al., 2010, Nutt and Stahl, 2010). However 5-
subunits are not likely to play an important role in the TMN (May et al., 2013). 
Considering 5-subunits are expressed mainly in the hippocampus (Hörtnagl et al., 
2013) and that genetic deletion of the 5-subunit enhances spatial memory in mice 
(Collinson et al., 2002), the main differences between zopiclone and zolpidem would 
be regarding amnesic side-effects (Nutt and Stahl, 2010) rather than sleep 
promotion. 
 
The results of this study may also support the idea that BZs work in this way too. 
However BZs probably have more effects beyond what we have found here. For 
example, midazolam potency is diminished ~6 fold by the 2I77 point-mutation but 
potentiates GABAergic inhibition onto histaminergic neurons via 1 subunits (May et 
al., 2013). Further, 1M diazepam potentiates GABAA-2-I77 receptors expressed on 
HEK cells (Ramerstorfer et al., 2010). HDC-neurons of 2I77 mice respond to 
diazepam which has an EC50 that is 70% of the wild-type counterpart, and is 
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statistically not different (May et al., 2013). Zolpidem and zopiclone, on the other 
hand, only potentiate 2I77-GABAA receptors to a negligible extent at concentrations 
as high as 10M in HEK cells (Ramerstorfer et al., 2010). Paradoxically TMN 
neurons harbour a small degree of zolpidem sensitivity via 1 subunits (May et al., 
2013). However the in vivo work in this study demonstrates that this level of 
sensitivity does not confer sleep. 
 
Diazepam begins to potentiate 2-GABAA bearing receptors at low concentrations 
(10 nm)(Ramerstorfer et al., 2010). Considering diazepam is also a therapeutic 
anxiolytic (Benham et al., 2014), it is interesting to see that at low doses, diazepam 
is somewhat selective for 2 containing receptors (Ramerstorfer et al., 2010). Not 
only was the 2-subunit found to confer the anxiolytic property of diazepam (Löw et 
al., 2000), 2 subunits are enriched in the amygdala (Pirker et al., 2000, Wisden et 
al., 1992). Perhaps the anxiety-promoting amygdala (Davis and Whalen, 2001) is 
particularly sensitive to inhibition by diazepam, so at low doses anxiolytic effects are 
favoured before other effects like sedation can manifest. Indeed it may be that 2 
selective GABAA receptor PAMs could replace BZs as anxiolytics (Benham et al., 
2014). Moreover the fact that zolpidem and zolpiclone are more selective for 1-
subunits supports their status as better sedative-hypnotics than BZs. It is also 
interesting to see that at very high doses (10mM) all three drugs preferentially 
potentiate 3 subunit containing receptors (Ramerstorfer et al., 2010). It suggests 
that, although these drugs are safe sedatives with respect to over-dosing, their 
therapeutic properties probably work by the “goldilocks principle” – more is not 
necessarily better. 
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5.2 Other brain areas 
 
Because global histamine tone is important for wake-promotion (Anaclet et al., 2009, 
Monnier et al., 1967, Nicholson et al., 1991, Parmentier et al., 2002, Parmentier et 
al., 2009, Yu et al., 2015) but the source is localized (Wada et al., 1991, Watanabe 
et al., 1984); local inhibition of this nodal point can cause global effects. With this in 
mind, other wake-promoting areas with similar hub-like arrangements are also 
probably important in zolpidem-sedation. Indeed the orexinergic LHA – the other 
major hypothalamic wake area (Saper et al., 2010) – might play a similar role as the 
TMN. The LHA has moderate to strong expression of 1, 2 & 3 subunits as well 
as 2 subunits, meaning the area is necessarily sensitive to zolpidem (Pirker et al., 
2000). In line with this, eszopiclone infusion into the LHA promotes sleep (Kumar et 
al., 2011). Just as we have introduced zolpidem-sensitivity in HDC-neurons to find 
an in vivo zolpidem response virtually identical to that of H1 receptor antagonist 
pyrilamine; it would be interesting to apply the same transgenic methods to a series 
of experiments in the LHA to see if zolpidem would produce the same effect as 
DORAs. Considering histamine receptor antagonists are long known – but not 
preferred – sedatives, this work on the orexin system would be interesting. 
Especially because DORAs are newer class of hypnotic-drug which ushers in an 
opportunity to move away from targeting GABAA receptors; and we have now seen 
that sedation does not require global targets, such as GABAA receptors. Orexin 
receptors may become more important in the future, as targets for hypnotic 
therapeutics (Scammell and Winrow, 2011, Bettica et al., 2012, Uslaner et al., 2013). 
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Ascending arousal areas posterior to the hypothalamus may also be involved in 
zolpidem’s sleep promoting effects. These include parts of the cholinergic 
parabrachial area of the midbrain/pons. The parabrachial area expresses 1, 2 & 
3 subunits (Pirker et al., 2000). More specifically, in situ hybridization labelling 
indicates the medial part expresses 2 subunits very strongly whereas the lateral part 
preferentially expresses 1 (Araki et al., 1992a, Araki et al., 1992b). Another 
ascending wake area which may be involve in zolpidem-mediated sleep is the 
gigantocellular reticular formation, in which moderate to strong 2 subunit mRNA 
levels occur, whereas weak 1 subunit mRNA levels occur (Araki et al., 1992b, Araki 
et al., 1992a). 
 
However, it seems unlikely that every arousal area is involved in zolpidem-mediated 
sleep. For instance, the serotonergic dorsal RN and the noradrenergic LC are 
broadly involved in sleep-wake control (Aston-Jones and Bloom, 1981, Kocsis et al., 
2006, Saper et al., 2010). However, due the expression pattern of particular GABAA 
receptor isoforms, neither nucleus is likely to be important for zolpidem-mediated 
sleep per se. The noradrenergic LC has no 2-subunits but it does have 1-subunits. 
And although few cells in the dorsal RN have 2-subunits, they densely express 1 
subunits. Importantly, in our study, we did not target wake-promoting areas 
indiscriminately. Because the “2-swap” method involves introducing 2-subunits 
transgenically, 2-subunits can be made to express, in principle, anywhere we target. 
Had we done experiments in the dorsal RN, for instance, we may have observed an 
effect upon sleep-wake behaviour. However it would be wrong to attribute 
importance of the effect to zolpidem’s mechanism, because employing the technique 
in a brain area that does not naturally utilize 2-subunits would be irrelevant. Indeed 
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the results may be interesting, in the same way studies that use DREADD receptors 
are, but it would only be relevant for systems neurophysiology in general, not the 
neuropharmacology of zolpidem per se. 
 
5.3 General anaesthesia 
 
In the L6-2 experiments we observed a clear effect of reduced sensitivity to 
isoflurane. But effects on normal sleep-wake were subtle. This opens up some 
interesting possible interpretations. The first, which seems most likely, is that 
because this was a chronic-knockout study, genetic compensation conserved the 
phenotype as discussed in the chapter 4 discussion (section 4.3). A second 
possibility is that the study illustrates a genuine dichotomy between the physiologic 
mechanisms of sleep-wake and the pharmacologic mechanisms of general 
anaesthesia. It may be tempting to infer that in physiology, inhibiting the tonic 
excitatory drive onto TC-neurons from ascending wake-promoting areas is more 
important in the initial transition into NREM sleep and inhibition of the tonic excitatory 
drive descending from the cortex is secondary to this; but in general anaesthesia it is 
the descending excitatory input that becomes dampened to facilitate a shift to burst-
firing in TC-neurons. However, this idea of top-down anaesthesia, versus bottom-up 
natural waking seems over-simplified. It seems, rather, that top-down and bottom-up 
mechanisms are involved in various aspects of general anaesthesia. For example, 
although we saw isoflurane anaesthetic induction and maintenance diminished by 
lesioning phasic GABAergic inhibition of thalamic excitatory drive from descending 
inputs; we saw no effect upon emergence from anaesthesia. Interestingly, injections 
of nicotine into the thalamus induces emergence from sevoflurane anaesthesia 
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(Alkire et al., 2007). This pharmacologic enhancement of some of the key ascending 
excitatory inputs to the thalamus – i.e. cholinergic innervation from the 
pedunculopontine & latero-dorsal tegmental nuclei (Franks, 2008, Fuller et al., 2011) 
– suggests a role of ascending arousal nuclei in emergence from anaesthesia (Alkire 
et al., 2007). Note also that the descending excitatory inputs are not cholinergic 
(Franks, 2008). Together, the evidence suggests that anaesthetics may induce LOC 
by impinging on descending excitatory circuitry, but the brain restores consciousness 
via ascending excitatory circuitry. The work by Luo and Leung (2011) mentioned in 
the introduction (section 1.6) would also support this notion, their study showed that 
lesioning the ascending wake-promoting TMN produced principal effects on the time 
until RRR  after isoflurane  anaesthesia (emergence) but no effect on time to LORR 
(induction). 
 
5.4 Conclusion 
 
Drugs that reversibly remove consciousness provide medicines that correct sleep – a 
basic vital requirement. They enable us to undergo surgery without experiencing it. 
Advances during recent medical history have revealed key molecular targets of 
these drugs. New evidence and technology has led investigators to speculate that 
these key targets provide their therapeutic effects due to their distribution throughout 
highly organized circuitry in the brain; constituting mechanisms that control 
experiences and behaviours. This thesis has demonstrated that in order for a 
hypnotic drug to work, it needs to influence physiologically relevant brain circuitry. 
This work supports the importance of neocortical-thalamic circuitry as well as 
hypothalamic wake-promoting nuclei, in the control of drug induced LOC. 
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Appendix 1. 
 
An HDC-promoter derived sequence is a pan promoter of AAV-mediated 
protein expression and successfully targets HDC neurons. a, AAV transgene 
allele. AAV-ITR flanked construct containing the pan-promoter sequence derived 
from the murine HDC-promoter. b, Schematic of microinjection site into TMN area of 
a mouse brain. c, Micrograph of transduced area including parts of the posterior 
hypothalamus, marked with Venus-protein and stained by immunohistochemistry 
using anti-GFP antisera. d, Transduced neurons labelled with anti-GFP antisera. e, 
The same transduced cells counter stained with anti-HDC antisera. f, Merged image 
revealing co-localization, showing HDC-neurons are transduced by the AAV 
construct.
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Appendix 2 
 
EEG analysis: Zolpidem in C57BL/6 mice and 2I77lox mice a, The percentage 
EEG power after IP injections of saline (open circles) or 1 mg/kg zolpidem (closed 
circles), relative to baseline recordings taken immediately before the injections in 
C57BL/6 (left) and 2I77lox mice (right). b, The same analysis with 5 mg/kg zolpidem 
in C57BL/6 mice (left) and 2I77lox mice (right). c, The analysis with 10 mg/kg 
zolpidem in C57BL/6 mice (left) and 2I77lox mice (right). d, The analysis with 20 
mg/kg zolpidem. Error bars represent SEM, n=3. 
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Appendix 3. 
 
Drug-induced NREM sleep bout-number and bout-length. Data points represent 
individual bouts (i.e. the bout-number) after a dose of saline (open circles), zolpidem 
(5 mg/kg, blue closed circles) and pyrilamine (5mg/kg; black closed circles). The 
duration of each bout is represented by its position on the y-axis. Data from 
individual mice are plotted side by side, grouped by mouse type. 
